WO2016039939A1 - Composés 2-pyridinone antibactériens à substitution bicyclique et tricyclique - Google Patents
Composés 2-pyridinone antibactériens à substitution bicyclique et tricyclique Download PDFInfo
- Publication number
- WO2016039939A1 WO2016039939A1 PCT/US2015/045440 US2015045440W WO2016039939A1 WO 2016039939 A1 WO2016039939 A1 WO 2016039939A1 US 2015045440 W US2015045440 W US 2015045440W WO 2016039939 A1 WO2016039939 A1 WO 2016039939A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino
- galkyl
- galky
- ethyl
- oxo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 372
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 125000002619 bicyclic group Chemical group 0.000 title claims abstract description 10
- 230000000844 anti-bacterial effect Effects 0.000 title description 21
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims abstract description 169
- 238000000034 method Methods 0.000 claims abstract description 70
- -1 amino-Ci_8alkyl Chemical group 0.000 claims description 638
- 239000002253 acid Substances 0.000 claims description 258
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 185
- 125000003118 aryl group Chemical group 0.000 claims description 108
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 83
- 239000003814 drug Substances 0.000 claims description 74
- 125000000623 heterocyclic group Chemical group 0.000 claims description 74
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 72
- 229940079593 drug Drugs 0.000 claims description 59
- 150000003839 salts Chemical class 0.000 claims description 57
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 56
- 125000004122 cyclic group Chemical group 0.000 claims description 49
- 125000001072 heteroaryl group Chemical group 0.000 claims description 46
- 239000012453 solvate Substances 0.000 claims description 46
- 229940002612 prodrug Drugs 0.000 claims description 43
- 239000000651 prodrug Substances 0.000 claims description 43
- 150000002367 halogens Chemical class 0.000 claims description 40
- 125000001424 substituent group Chemical group 0.000 claims description 38
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims description 37
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 32
- 229910052736 halogen Inorganic materials 0.000 claims description 30
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 25
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 25
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 239000001257 hydrogen Substances 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 21
- 125000005241 heteroarylamino group Chemical group 0.000 claims description 21
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 20
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 20
- 125000001769 aryl amino group Chemical group 0.000 claims description 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
- 230000003115 biocidal effect Effects 0.000 claims description 14
- KTCNGKASVZVXHT-UHFFFAOYSA-N 1,2-dihydropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CNC1 KTCNGKASVZVXHT-UHFFFAOYSA-N 0.000 claims description 13
- 239000003242 anti bacterial agent Substances 0.000 claims description 13
- 238000002648 combination therapy Methods 0.000 claims description 12
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims description 11
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 11
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 8
- 125000006308 propyl amino group Chemical group 0.000 claims description 8
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 7
- 125000004043 oxo group Chemical group O=* 0.000 claims description 6
- OYENBHGGTQRCRM-UHFFFAOYSA-N 5-ethyl-4-hydroxy-2-oxo-6-(1,2,3,4-tetrahydroquinoxalin-6-yl)-1H-pyridine-3-carboxylic acid Chemical compound C(C)C=1C(=C(C(NC=1C=1C=C2NCCNC2=CC=1)=O)C(=O)O)O OYENBHGGTQRCRM-UHFFFAOYSA-N 0.000 claims description 4
- USCWULUCUJTGHD-UHFFFAOYSA-N 5-ethyl-4-hydroxy-2-oxo-6-(1,2,3,4-tetrahydroquinoxalin-6-yl)-1H-pyridine-3-carboxylic acid hydrochloride Chemical compound CCC1=C(NC(=O)C(=C1O)C(=O)O)C2=CC3=C(C=C2)NCCN3.Cl USCWULUCUJTGHD-UHFFFAOYSA-N 0.000 claims description 4
- DNMNJXFSMYEFRE-UHFFFAOYSA-N 5-ethyl-6-(1,2,3,4,5,10-hexahydroazepino[3,4-b]indol-8-yl)-4-hydroxy-2-oxo-1H-pyridine-3-carboxylic acid Chemical compound C(C)C=1C(=C(C(NC=1C1=CC=C2C3=C(NC2=C1)CNCCC3)=O)C(=O)O)O DNMNJXFSMYEFRE-UHFFFAOYSA-N 0.000 claims description 4
- RBAVDWFURFGWTJ-UHFFFAOYSA-N 5-ethyl-6-(1,2,3,4,5,6-hexahydroazepino[4,5-b]indol-8-yl)-4-hydroxy-2-oxo-1H-pyridine-3-carboxylic acid Chemical compound C(C)C=1C(=C(C(NC=1C=1C=CC=2C3=C(NC=2C=1)CCNCC3)=O)C(=O)O)O RBAVDWFURFGWTJ-UHFFFAOYSA-N 0.000 claims description 4
- ZKVIJHHXUUXYFD-UHFFFAOYSA-N C(C)C=1C(=C(C(NC=1C=1C=C2C=C(N(C2=CC=1)C)CCO)=O)C(=O)O)O Chemical compound C(C)C=1C(=C(C(NC=1C=1C=C2C=C(N(C2=CC=1)C)CCO)=O)C(=O)O)O ZKVIJHHXUUXYFD-UHFFFAOYSA-N 0.000 claims description 4
- BABJUBNGSUZYGG-UHFFFAOYSA-N C(C)C=1C(=C(C(NC=1C=1C=CC=2C3=C(NC=2C=1)CCN(CC3)C)=O)C(=O)O)O Chemical compound C(C)C=1C(=C(C(NC=1C=1C=CC=2C3=C(NC=2C=1)CCN(CC3)C)=O)C(=O)O)O BABJUBNGSUZYGG-UHFFFAOYSA-N 0.000 claims description 4
- WJCAFNXZLYVKAY-UHFFFAOYSA-N CN(C(C)C=1NC2=CC(=CC=C2C=1)C1=C(C(=C(C(N1)=O)C(=O)O)O)CC)C Chemical compound CN(C(C)C=1NC2=CC(=CC=C2C=1)C1=C(C(=C(C(N1)=O)C(=O)O)O)CC)C WJCAFNXZLYVKAY-UHFFFAOYSA-N 0.000 claims description 4
- MPLOLXBHBXPSLJ-UHFFFAOYSA-N CN(C)CC=1NC2=CC(=CC=C2C=1C(F)(F)F)C1=C(C(=C(C(N1)=O)C(=O)O)O)CC Chemical compound CN(C)CC=1NC2=CC(=CC=C2C=1C(F)(F)F)C1=C(C(=C(C(N1)=O)C(=O)O)O)CC MPLOLXBHBXPSLJ-UHFFFAOYSA-N 0.000 claims description 4
- VWQPDKXCXHOZPO-UHFFFAOYSA-N N.CCc1c(O)c(C(O)=O)c(=O)[nH]c1-c1ccc2c(F)c(CN(C)C)[nH]c2c1 Chemical compound N.CCc1c(O)c(C(O)=O)c(=O)[nH]c1-c1ccc2c(F)c(CN(C)C)[nH]c2c1 VWQPDKXCXHOZPO-UHFFFAOYSA-N 0.000 claims description 4
- JCAIMBOXMOVBSY-UHFFFAOYSA-N NCCC=1N(C2=CC=C(C=C2C=1)C1=C(C(=C(C(N1)=O)C(=O)O)O)CC)C Chemical compound NCCC=1N(C2=CC=C(C=C2C=1)C1=C(C(=C(C(N1)=O)C(=O)O)O)CC)C JCAIMBOXMOVBSY-UHFFFAOYSA-N 0.000 claims description 4
- JAWKGPCWIMYBMM-UHFFFAOYSA-N C(C)C=1C(=C(C(NC=1C1=CC=C2C(=C(NC2=C1)CNCC)C(F)(F)F)=O)C(=O)O)O Chemical compound C(C)C=1C(=C(C(NC=1C1=CC=C2C(=C(NC2=C1)CNCC)C(F)(F)F)=O)C(=O)O)O JAWKGPCWIMYBMM-UHFFFAOYSA-N 0.000 claims description 3
- GDDOPNXOHHLTPO-UHFFFAOYSA-N C(C)C=1C(=C(C(NC=1C1=CC=C2C3=C(NC2=C1)CN(CCC3)C)=O)C(=O)O)O Chemical compound C(C)C=1C(=C(C(NC=1C1=CC=C2C3=C(NC2=C1)CN(CCC3)C)=O)C(=O)O)O GDDOPNXOHHLTPO-UHFFFAOYSA-N 0.000 claims description 3
- IPQIRCJIAIBDOI-UHFFFAOYSA-N CCC1=C(NC(=O)C(C(O)=O)=C1O)C1=CC=C2NC(C)=NC2=C1 Chemical compound CCC1=C(NC(=O)C(C(O)=O)=C1O)C1=CC=C2NC(C)=NC2=C1 IPQIRCJIAIBDOI-UHFFFAOYSA-N 0.000 claims description 3
- UINRBDRLAVBHGK-UHFFFAOYSA-N S1CCNC2=C1C=CC(=C2)C1=C(C(=C(C(N1)=O)C(=O)O)O)CC Chemical compound S1CCNC2=C1C=CC(=C2)C1=C(C(=C(C(N1)=O)C(=O)O)O)CC UINRBDRLAVBHGK-UHFFFAOYSA-N 0.000 claims description 3
- FMBBYTZDDYFVDI-UHFFFAOYSA-N C(C)C=1C(=C(C(NC=1C=1C=C2C=C(N(C2=CC=1)C)CCNCC)=O)C(=O)O)O Chemical compound C(C)C=1C(=C(C(NC=1C=1C=C2C=C(N(C2=CC=1)C)CCNCC)=O)C(=O)O)O FMBBYTZDDYFVDI-UHFFFAOYSA-N 0.000 claims description 2
- PTTBHVWCUDEJJO-UHFFFAOYSA-N Cl.CCc1c(O)c(C(O)=O)c(=O)[nH]c1-c1ccc2c3CCCN(C)Cc3[nH]c2c1 Chemical compound Cl.CCc1c(O)c(C(O)=O)c(=O)[nH]c1-c1ccc2c3CCCN(C)Cc3[nH]c2c1 PTTBHVWCUDEJJO-UHFFFAOYSA-N 0.000 claims 2
- CCPMNQZIQBFOES-UHFFFAOYSA-N Cl.CCc1c(O)c(C(O)=O)c(=O)[nH]c1-c1ccc2c3CCN(C)CCc3[nH]c2c1 Chemical compound Cl.CCc1c(O)c(C(O)=O)c(=O)[nH]c1-c1ccc2c3CCN(C)CCc3[nH]c2c1 CCPMNQZIQBFOES-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 77
- 150000003254 radicals Chemical class 0.000 description 137
- 238000005160 1H NMR spectroscopy Methods 0.000 description 63
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 61
- 230000000694 effects Effects 0.000 description 47
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 43
- 239000000543 intermediate Substances 0.000 description 43
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 42
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 32
- 239000003795 chemical substances by application Substances 0.000 description 31
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 28
- 229910001868 water Inorganic materials 0.000 description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 24
- 239000004098 Tetracycline Substances 0.000 description 21
- 229960003405 ciprofloxacin Drugs 0.000 description 21
- 229960002180 tetracycline Drugs 0.000 description 21
- 229930101283 tetracycline Natural products 0.000 description 21
- 235000019364 tetracycline Nutrition 0.000 description 21
- 150000003522 tetracyclines Chemical class 0.000 description 21
- 238000011282 treatment Methods 0.000 description 21
- 150000002148 esters Chemical class 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 235000019439 ethyl acetate Nutrition 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 17
- 229960005322 streptomycin Drugs 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 125000001041 indolyl group Chemical group 0.000 description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 12
- 125000004076 pyridyl group Chemical group 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 229960000723 ampicillin Drugs 0.000 description 11
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 11
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 11
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 11
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 11
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 11
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 11
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 229930182555 Penicillin Natural products 0.000 description 10
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 10
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 10
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 10
- 229940049954 penicillin Drugs 0.000 description 10
- 150000003222 pyridines Chemical class 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 229960004755 ceftriaxone Drugs 0.000 description 8
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 230000000996 additive effect Effects 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 229960002129 cefixime Drugs 0.000 description 7
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 7
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 6
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 6
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 6
- 125000005960 1,4-diazepanyl group Chemical group 0.000 description 6
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 6
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 102000008100 Human Serum Albumin Human genes 0.000 description 6
- 108091006905 Human Serum Albumin Proteins 0.000 description 6
- 229910002666 PdCl2 Inorganic materials 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 125000002393 azetidinyl group Chemical group 0.000 description 6
- 229960004099 azithromycin Drugs 0.000 description 6
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 125000001475 halogen functional group Chemical group 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 125000002757 morpholinyl group Chemical group 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 6
- 125000004193 piperazinyl group Chemical group 0.000 description 6
- 125000003386 piperidinyl group Chemical group 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 125000000168 pyrrolyl group Chemical group 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 6
- 125000000335 thiazolyl group Chemical group 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 125000005983 2,5-diazabicyclo[2.2.1]heptan-2-yl group Chemical group 0.000 description 5
- YFTHTJAPODJVSL-UHFFFAOYSA-N 2-(1-benzothiophen-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(SC=C2)C2=C1 YFTHTJAPODJVSL-UHFFFAOYSA-N 0.000 description 5
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 5
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 5
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 5
- 229930186147 Cephalosporin Natural products 0.000 description 5
- 101100398610 Felis catus LGB3 gene Proteins 0.000 description 5
- 238000003461 Miyaura Borylation reaction Methods 0.000 description 5
- 238000006069 Suzuki reaction reaction Methods 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 229940126575 aminoglycoside Drugs 0.000 description 5
- 150000005347 biaryls Chemical class 0.000 description 5
- 239000012455 biphasic mixture Substances 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 229940124587 cephalosporin Drugs 0.000 description 5
- 150000001780 cephalosporins Chemical class 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 150000004678 hydrides Chemical class 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000003120 macrolide antibiotic agent Substances 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 5
- 125000004574 piperidin-2-yl group Chemical group N1C(CCCC1)* 0.000 description 5
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 5
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 229960000268 spectinomycin Drugs 0.000 description 5
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 5
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 5
- 150000003952 β-lactams Chemical class 0.000 description 5
- IXXFZUPTQVDPPK-ZAWHAJPISA-N (1r,2r,4r,6r,7r,8r,10s,13r,14s)-17-[4-[4-(3-aminophenyl)triazol-1-yl]butyl]-7-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-10-fluoro-6-methoxy-2,4,6,8,10,14-hexamethyl-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tet Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@](C)(F)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3N=NC(=C3)C=3C=C(N)C=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O IXXFZUPTQVDPPK-ZAWHAJPISA-N 0.000 description 4
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 4
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 4
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 4
- 229930182566 Gentamicin Natural products 0.000 description 4
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 241000988233 Neisseria gonorrhoeae FA 1090 Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229960003022 amoxicillin Drugs 0.000 description 4
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 235000019445 benzyl alcohol Nutrition 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 4
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000007859 condensation product Substances 0.000 description 4
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 4
- 229960003722 doxycycline Drugs 0.000 description 4
- 229960002549 enoxacin Drugs 0.000 description 4
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 229960003923 gatifloxacin Drugs 0.000 description 4
- 229960003170 gemifloxacin Drugs 0.000 description 4
- ZRCVYEYHRGVLOC-HYARGMPZSA-N gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 description 4
- 229960002518 gentamicin Drugs 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229960003376 levofloxacin Drugs 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 4
- 229960002422 lomefloxacin Drugs 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 229960003702 moxifloxacin Drugs 0.000 description 4
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 4
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 4
- 229960000210 nalidixic acid Drugs 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 4
- 229960001180 norfloxacin Drugs 0.000 description 4
- 229960001699 ofloxacin Drugs 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 4
- 229960001225 rifampicin Drugs 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 4
- 229960002930 sirolimus Drugs 0.000 description 4
- 229950008588 solithromycin Drugs 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- UEYQJQVBUVAELZ-UHFFFAOYSA-N 2-Hydroxynicotinic acid Chemical compound OC(=O)C1=CC=CN=C1O UEYQJQVBUVAELZ-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 3
- 241001108456 Neisseria gonorrhoeae FA19 Species 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- IINBAFXWKBIVKR-UHFFFAOYSA-N benzyl 6-chloro-5-ethyl-2,4-bis(phenylmethoxy)pyridine-3-carboxylate Chemical compound C=1C=CC=CC=1COC(=O)C1=C(OCC=2C=CC=CC=2)C(CC)=C(Cl)N=C1OCC1=CC=CC=C1 IINBAFXWKBIVKR-UHFFFAOYSA-N 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000013066 combination product Substances 0.000 description 3
- 229940127555 combination product Drugs 0.000 description 3
- 239000012084 conversion product Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 150000004667 medium chain fatty acids Chemical class 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Substances C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- QKQLJJFOYPGDEX-BZDVOYDHSA-N (2s)-2-[2-[[(2s)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol;dihydrobromide Chemical compound Br.Br.CC[C@@H](CO)NCCN[C@@H](CC)CO QKQLJJFOYPGDEX-BZDVOYDHSA-N 0.000 description 2
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 2
- SOVUOXKZCCAWOJ-HJYUBDRYSA-N (4s,4as,5ar,12ar)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O SOVUOXKZCCAWOJ-HJYUBDRYSA-N 0.000 description 2
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 2
- GPYKKBAAPVOCIW-HSASPSRMSA-N (6r,7s)-7-[[(2r)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate Chemical compound O.C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 GPYKKBAAPVOCIW-HSASPSRMSA-N 0.000 description 2
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 2
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- ZEZJPIDPVXJEME-UHFFFAOYSA-N 2,4-Dihydroxypyridine Chemical group OC=1C=CNC(=O)C=1 ZEZJPIDPVXJEME-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 108010065839 Capreomycin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZMUANUAOJMPGEY-UHFFFAOYSA-N Cl.CCNCCc1cc2cc(ccc2n1C)-c1[nH]c(=O)c(C(O)=O)c(O)c1CC Chemical compound Cl.CCNCCc1cc2cc(ccc2n1C)-c1[nH]c(=O)c(C(O)=O)c(O)c1CC ZMUANUAOJMPGEY-UHFFFAOYSA-N 0.000 description 2
- ACTKTTRDDQEDQA-UHFFFAOYSA-N Cl.CCc1c(O)c(C(O)=O)c(=O)[nH]c1-c1ccc2SCCNc2c1 Chemical compound Cl.CCc1c(O)c(C(O)=O)c(=O)[nH]c1-c1ccc2SCCNc2c1 ACTKTTRDDQEDQA-UHFFFAOYSA-N 0.000 description 2
- QPIFHXRPKNKWFV-UHFFFAOYSA-N Cl.CCc1c(O)c(C(O)=O)c(=O)[nH]c1-c1ccc2cc([nH]c2c1)C(C)N(C)C Chemical compound Cl.CCc1c(O)c(C(O)=O)c(=O)[nH]c1-c1ccc2cc([nH]c2c1)C(C)N(C)C QPIFHXRPKNKWFV-UHFFFAOYSA-N 0.000 description 2
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 2
- 108010078777 Colistin Proteins 0.000 description 2
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 2
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 2
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 2
- 108010013198 Daptomycin Proteins 0.000 description 2
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 2
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 2
- TYMRLRRVMHJFTF-UHFFFAOYSA-N Mafenide Chemical compound NCC1=CC=C(S(N)(=O)=O)C=C1 TYMRLRRVMHJFTF-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- 241001108452 Neisseria gonorrhoeae MS11 Species 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- FOERTBXCWDXAIU-UHFFFAOYSA-N O1CCNC2=C1C=CC(=C2)C1=C(C(=C(C(N1)=O)C(=O)O)O)CC Chemical compound O1CCNC2=C1C=CC(=C2)C1=C(C(=C(C(N1)=O)C(=O)O)O)CC FOERTBXCWDXAIU-UHFFFAOYSA-N 0.000 description 2
- LPWNFGCXXBEUMQ-UHFFFAOYSA-N OC1=C(C(NC(=C1C)C=1C=CC=C2C=CN(C=12)C)=O)C(=O)O Chemical compound OC1=C(C(NC(=C1C)C=1C=CC=C2C=CN(C=12)C)=O)C(=O)O LPWNFGCXXBEUMQ-UHFFFAOYSA-N 0.000 description 2
- 239000004100 Oxytetracycline Substances 0.000 description 2
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 2
- 229930195708 Penicillin V Natural products 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 108010093965 Polymyxin B Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108010013381 Porins Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 2
- 108010053950 Teicoplanin Proteins 0.000 description 2
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 2
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229960004821 amikacin Drugs 0.000 description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229940003446 arsphenamine Drugs 0.000 description 2
- VLAXZGHHBIJLAD-UHFFFAOYSA-N arsphenamine Chemical compound [Cl-].[Cl-].C1=C(O)C([NH3+])=CC([As]=[As]C=2C=C([NH3+])C(O)=CC=2)=C1 VLAXZGHHBIJLAD-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960003623 azlocillin Drugs 0.000 description 2
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 2
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 2
- 229960003644 aztreonam Drugs 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229960004602 capreomycin Drugs 0.000 description 2
- 229960003669 carbenicillin Drugs 0.000 description 2
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 2
- 229960005361 cefaclor Drugs 0.000 description 2
- 229960004841 cefadroxil Drugs 0.000 description 2
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 2
- 229960000603 cefalotin Drugs 0.000 description 2
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 2
- 229960003012 cefamandole Drugs 0.000 description 2
- 229960001139 cefazolin Drugs 0.000 description 2
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 2
- 229960003719 cefdinir Drugs 0.000 description 2
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 2
- 229960004069 cefditoren Drugs 0.000 description 2
- KMIPKYQIOVAHOP-YLGJWRNMSA-N cefditoren Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C/C=1SC=NC=1C KMIPKYQIOVAHOP-YLGJWRNMSA-N 0.000 description 2
- 229960004682 cefoperazone Drugs 0.000 description 2
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 2
- 229960004261 cefotaxime Drugs 0.000 description 2
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 2
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 2
- 229960002682 cefoxitin Drugs 0.000 description 2
- 229960005090 cefpodoxime Drugs 0.000 description 2
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 2
- 229960002580 cefprozil Drugs 0.000 description 2
- 229960000484 ceftazidime Drugs 0.000 description 2
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 2
- 229960004086 ceftibuten Drugs 0.000 description 2
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 description 2
- 229960001991 ceftizoxime Drugs 0.000 description 2
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 2
- 229960001668 cefuroxime Drugs 0.000 description 2
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229940106164 cephalexin Drugs 0.000 description 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- DHSUYTOATWAVLW-WFVMDLQDSA-N cilastatin Chemical compound CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O DHSUYTOATWAVLW-WFVMDLQDSA-N 0.000 description 2
- 229960004912 cilastatin Drugs 0.000 description 2
- 229960002626 clarithromycin Drugs 0.000 description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 2
- 229940090805 clavulanate Drugs 0.000 description 2
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 229960004287 clofazimine Drugs 0.000 description 2
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 2
- 229960003346 colistin Drugs 0.000 description 2
- 229960003077 cycloserine Drugs 0.000 description 2
- 229960002615 dalfopristin Drugs 0.000 description 2
- SUYRLXYYZQTJHF-VMBLUXKRSA-N dalfopristin Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1 SUYRLXYYZQTJHF-VMBLUXKRSA-N 0.000 description 2
- 108700028430 dalfopristin Proteins 0.000 description 2
- 229960000860 dapsone Drugs 0.000 description 2
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 2
- 229960005484 daptomycin Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 2
- 229960001585 dicloxacillin Drugs 0.000 description 2
- 229960004100 dirithromycin Drugs 0.000 description 2
- WLOHNSSYAXHWNR-NXPDYKKBSA-N dirithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H]2O[C@H](COCCOC)N[C@H]([C@@H]2C)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 WLOHNSSYAXHWNR-NXPDYKKBSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 229960000895 doripenem Drugs 0.000 description 2
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229960000285 ethambutol Drugs 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Natural products CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 2
- 229960002001 ethionamide Drugs 0.000 description 2
- 229960004273 floxacillin Drugs 0.000 description 2
- 229940124307 fluoroquinolone Drugs 0.000 description 2
- 229960000308 fosfomycin Drugs 0.000 description 2
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960001625 furazolidone Drugs 0.000 description 2
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 2
- 229960004675 fusidic acid Drugs 0.000 description 2
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229960002182 imipenem Drugs 0.000 description 2
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 229960003350 isoniazid Drugs 0.000 description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960005287 lincomycin Drugs 0.000 description 2
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 2
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 2
- 229960003907 linezolid Drugs 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 229960001977 loracarbef Drugs 0.000 description 2
- 229960003640 mafenide Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960002260 meropenem Drugs 0.000 description 2
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 2
- 229960000198 mezlocillin Drugs 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 229960004023 minocycline Drugs 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229960003128 mupirocin Drugs 0.000 description 2
- 229930187697 mupirocin Natural products 0.000 description 2
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 2
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 2
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 2
- 229960000515 nafcillin Drugs 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 229960000808 netilmicin Drugs 0.000 description 2
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 2
- 229960000564 nitrofurantoin Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 2
- 229960001019 oxacillin Drugs 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 229960000625 oxytetracycline Drugs 0.000 description 2
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 2
- 235000019366 oxytetracycline Nutrition 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 2
- 229960001914 paromomycin Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 229940056367 penicillin v Drugs 0.000 description 2
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 229960002292 piperacillin Drugs 0.000 description 2
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 2
- CSOMAHTTWTVBFL-OFBLZTNGSA-N platensimycin Chemical compound C([C@]1([C@@H]2[C@@H]3C[C@@H]4C[C@@]2(C=CC1=O)C[C@@]4(O3)C)C)CC(=O)NC1=C(O)C=CC(C(O)=O)=C1O CSOMAHTTWTVBFL-OFBLZTNGSA-N 0.000 description 2
- CSOMAHTTWTVBFL-UHFFFAOYSA-N platensimycin Natural products O1C2(C)CC3(C=CC4=O)CC2CC1C3C4(C)CCC(=O)NC1=C(O)C=CC(C(O)=O)=C1O CSOMAHTTWTVBFL-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920000024 polymyxin B Polymers 0.000 description 2
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 2
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 2
- 229960005266 polymyxin b Drugs 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 102000007739 porin activity proteins Human genes 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- LBKJNHPKYFYCLL-UHFFFAOYSA-N potassium;trimethyl(oxido)silane Chemical compound [K+].C[Si](C)(C)[O-] LBKJNHPKYFYCLL-UHFFFAOYSA-N 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229960005206 pyrazinamide Drugs 0.000 description 2
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 2
- 150000007660 quinolones Chemical class 0.000 description 2
- WTHRRGMBUAHGNI-LCYNINFDSA-N quinupristin Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O WTHRRGMBUAHGNI-LCYNINFDSA-N 0.000 description 2
- 229960005442 quinupristin Drugs 0.000 description 2
- 108700028429 quinupristin Proteins 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 229960000885 rifabutin Drugs 0.000 description 2
- 229960002599 rifapentine Drugs 0.000 description 2
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 description 2
- 229960003040 rifaximin Drugs 0.000 description 2
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 description 2
- 229960005224 roxithromycin Drugs 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229960003600 silver sulfadiazine Drugs 0.000 description 2
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 239000008137 solubility enhancer Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960005256 sulbactam Drugs 0.000 description 2
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 2
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 2
- 229960002673 sulfacetamide Drugs 0.000 description 2
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 2
- 229960004306 sulfadiazine Drugs 0.000 description 2
- 229960000654 sulfafurazole Drugs 0.000 description 2
- VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 2
- 229960005158 sulfamethizole Drugs 0.000 description 2
- 229960005404 sulfamethoxazole Drugs 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229960003865 tazobactam Drugs 0.000 description 2
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 description 2
- 229960001608 teicoplanin Drugs 0.000 description 2
- 229960005240 telavancin Drugs 0.000 description 2
- ONUMZHGUFYIKPM-MXNFEBESSA-N telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 description 2
- 108010089019 telavancin Proteins 0.000 description 2
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 description 2
- 229960003250 telithromycin Drugs 0.000 description 2
- 229960001114 temocillin Drugs 0.000 description 2
- BVCKFLJARNKCSS-DWPRYXJFSA-N temocillin Chemical compound N([C@]1(OC)C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C=1C=CSC=1 BVCKFLJARNKCSS-DWPRYXJFSA-N 0.000 description 2
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- OTVAEFIXJLOWRX-NXEZZACHSA-N thiamphenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)C=C1 OTVAEFIXJLOWRX-NXEZZACHSA-N 0.000 description 2
- 229960003053 thiamphenicol Drugs 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 229960004089 tigecycline Drugs 0.000 description 2
- 229960005053 tinidazole Drugs 0.000 description 2
- 229960000707 tobramycin Drugs 0.000 description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960001082 trimethoprim Drugs 0.000 description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 2
- 229960005041 troleandomycin Drugs 0.000 description 2
- LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- XFQNWPYGEGCIMF-HCUGAJCMSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].[Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 XFQNWPYGEGCIMF-HCUGAJCMSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- PAORVUMOXXAMPL-SECBINFHSA-N (2s)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl chloride Chemical compound CO[C@](C(Cl)=O)(C(F)(F)F)C1=CC=CC=C1 PAORVUMOXXAMPL-SECBINFHSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- AEMWUHCKKDPRSK-UHFFFAOYSA-N (ne)-n-diazo-2,4,6-tri(propan-2-yl)benzenesulfonamide Chemical compound CC(C)C1=CC(C(C)C)=C(S(=O)(=O)N=[N+]=[N-])C(C(C)C)=C1 AEMWUHCKKDPRSK-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- VOXZDWNPVJITMN-UHFFFAOYSA-N 13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2C3CCC(C)(C(CC4)O)C4C3CCC2=C1 VOXZDWNPVJITMN-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- ZVMHOIWRCCZGPZ-UHFFFAOYSA-N 1h-indol-6-ylboronic acid Chemical compound OB(O)C1=CC=C2C=CNC2=C1 ZVMHOIWRCCZGPZ-UHFFFAOYSA-N 0.000 description 1
- UUDALWDRIFYZPM-UHFFFAOYSA-N 1h-pyridine-2,4-dione Chemical group O=C1CC(=O)C=CN1 UUDALWDRIFYZPM-UHFFFAOYSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- JBKINHFZTVLNEM-UHFFFAOYSA-N 2-bromoethoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCBr JBKINHFZTVLNEM-UHFFFAOYSA-N 0.000 description 1
- RBYJMZPBKPNJQA-UHFFFAOYSA-N 2-chloro-3-ethyl-4,6-bis(phenylmethoxy)pyridine Chemical compound C1=C(OCC=2C=CC=CC=2)C(CC)=C(Cl)N=C1OCC1=CC=CC=C1 RBYJMZPBKPNJQA-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- SXXLKZCNJHJYFL-UHFFFAOYSA-N 4,5,6,7-tetrahydro-[1,2]oxazolo[4,5-c]pyridin-5-ium-3-olate Chemical compound C1CNCC2=C1ONC2=O SXXLKZCNJHJYFL-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- QBDHQCNQDWWIRK-UHFFFAOYSA-N 6-chloro-5-ethyl-4-hydroxy-1h-pyridin-2-one Chemical compound CCC=1C(O)=CC(=O)NC=1Cl QBDHQCNQDWWIRK-UHFFFAOYSA-N 0.000 description 1
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- LDOOOZWJVFHGBV-UHFFFAOYSA-N C(C)(=O)C=1N(C2=CC(=CC=C2C=1C)C1=NC(=C(C(=C1CC)OCC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1)OCC1=CC=CC=C1)C(=O)OC(C)(C)C Chemical compound C(C)(=O)C=1N(C2=CC(=CC=C2C=1C)C1=NC(=C(C(=C1CC)OCC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1)OCC1=CC=CC=C1)C(=O)OC(C)(C)C LDOOOZWJVFHGBV-UHFFFAOYSA-N 0.000 description 1
- HANYJRXLEDMTSH-UHFFFAOYSA-N C(C)(=O)C=1NC2=CC(=CC=C2C=1C)C1=NC(=C(C(=O)OCC2=CC=CC=C2)C(=C1CC)OCC1=CC=CC=C1)OCC1=CC=CC=C1 Chemical compound C(C)(=O)C=1NC2=CC(=CC=C2C=1C)C1=NC(=C(C(=O)OCC2=CC=CC=C2)C(=C1CC)OCC1=CC=CC=C1)OCC1=CC=CC=C1 HANYJRXLEDMTSH-UHFFFAOYSA-N 0.000 description 1
- RVGBWPZTLNRIMT-UHFFFAOYSA-N C(C)C=1C(=C(C(NC=1C1=CC=C2C(=C(NC2=C1)CN(C)CC)C)=O)C(=O)O)O Chemical compound C(C)C=1C(=C(C(NC=1C1=CC=C2C(=C(NC2=C1)CN(C)CC)C)=O)C(=O)O)O RVGBWPZTLNRIMT-UHFFFAOYSA-N 0.000 description 1
- NORBQQSKFMOWEL-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=C(C(=NC(=C1C(=O)OCC1=CC=CC=C1)OCC1=CC=CC=C1)C1=CC=C2C(=C(N(C2=C1)C(=O)OC(C)(C)C)C(CNC)=O)C)CC Chemical compound C(C1=CC=CC=C1)OC1=C(C(=NC(=C1C(=O)OCC1=CC=CC=C1)OCC1=CC=CC=C1)C1=CC=C2C(=C(N(C2=C1)C(=O)OC(C)(C)C)C(CNC)=O)C)CC NORBQQSKFMOWEL-UHFFFAOYSA-N 0.000 description 1
- BBHSDCSQLRJBLV-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=C(C(=O)OCC2=CC=CC=C2)C(=C(C(=N1)C1=C(C=C2C=CNC2=C1)F)CC)OCC1=CC=CC=C1 Chemical compound C(C1=CC=CC=C1)OC1=C(C(=O)OCC2=CC=CC=C2)C(=C(C(=N1)C1=C(C=C2C=CNC2=C1)F)CC)OCC1=CC=CC=C1 BBHSDCSQLRJBLV-UHFFFAOYSA-N 0.000 description 1
- WSMLVTWJARBCIY-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=C(C(=O)OCC2=CC=CC=C2)C(=C(C(=N1)C1=CC=C2C(=C(NC2=C1)C=O)C(F)(F)F)CC)OCC1=CC=CC=C1 Chemical compound C(C1=CC=CC=C1)OC1=C(C(=O)OCC2=CC=CC=C2)C(=C(C(=N1)C1=CC=C2C(=C(NC2=C1)C=O)C(F)(F)F)CC)OCC1=CC=CC=C1 WSMLVTWJARBCIY-UHFFFAOYSA-N 0.000 description 1
- GSRCIIKCBVHVHB-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=C(C(=O)OCC2=CC=CC=C2)C(=C(C(=N1)C1=CC=C2C(=C(NC2=C1)CN(C)C)C(F)(F)F)CC)OCC1=CC=CC=C1 Chemical compound C(C1=CC=CC=C1)OC1=C(C(=O)OCC2=CC=CC=C2)C(=C(C(=N1)C1=CC=C2C(=C(NC2=C1)CN(C)C)C(F)(F)F)CC)OCC1=CC=CC=C1 GSRCIIKCBVHVHB-UHFFFAOYSA-N 0.000 description 1
- FAIKVYXIMWRCMH-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=C(C(=O)OCC2=CC=CC=C2)C(=C(C(=N1)C1=CC=C2C=C(NC2=C1)CCOS(=O)(=O)C)CC)OCC1=CC=CC=C1 Chemical compound C(C1=CC=CC=C1)OC1=C(C(=O)OCC2=CC=CC=C2)C(=C(C(=N1)C1=CC=C2C=C(NC2=C1)CCOS(=O)(=O)C)CC)OCC1=CC=CC=C1 FAIKVYXIMWRCMH-UHFFFAOYSA-N 0.000 description 1
- XDKHAXCNUKCZCI-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=NC=C(C(=C1OCC1=CC=CC=C1)OCC1=CC=CC=C1)I Chemical compound C(C1=CC=CC=C1)OC1=NC=C(C(=C1OCC1=CC=CC=C1)OCC1=CC=CC=C1)I XDKHAXCNUKCZCI-UHFFFAOYSA-N 0.000 description 1
- YSQGDXHXIDSNAK-UHFFFAOYSA-N C(C1=CC=CC=C1)OC=1C(=NC=C(C=1Cl)I)Cl Chemical compound C(C1=CC=CC=C1)OC=1C(=NC=C(C=1Cl)I)Cl YSQGDXHXIDSNAK-UHFFFAOYSA-N 0.000 description 1
- CYQHVFZADFVOID-UHFFFAOYSA-N C(C1=CC=CC=C1)OC=1C(=NC=CC=1Cl)Cl Chemical compound C(C1=CC=CC=C1)OC=1C(=NC=CC=1Cl)Cl CYQHVFZADFVOID-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- SPQZBUZDNWMEHD-UHFFFAOYSA-N CC1=C(NC(=O)C(C(O)=O)=C1O)C1=C2NC=CC2=CC=C1 Chemical compound CC1=C(NC(=O)C(C(O)=O)=C1O)C1=C2NC=CC2=CC=C1 SPQZBUZDNWMEHD-UHFFFAOYSA-N 0.000 description 1
- HQTHEJFZOWHUNC-UHFFFAOYSA-N CN(CCC=1N(C2=CC=C(C=C2C=1)C1=C(C(=C(C(N1)=O)C(=O)O)O)CC)C)C Chemical compound CN(CCC=1N(C2=CC=C(C=C2C=1)C1=C(C(=C(C(N1)=O)C(=O)O)O)CC)C)C HQTHEJFZOWHUNC-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100189356 Mus musculus Papolb gene Proteins 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- VAWQQXNKJYTIKA-UHFFFAOYSA-N N(=[N+]=[N-])C=1C(=C(C(=NC=1)OCC1=CC=CC=C1)OCC1=CC=CC=C1)OCC1=CC=CC=C1 Chemical compound N(=[N+]=[N-])C=1C(=C(C(=NC=1)OCC1=CC=CC=C1)OCC1=CC=CC=C1)OCC1=CC=CC=C1 VAWQQXNKJYTIKA-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000007313 Reproductive Tract Infections Diseases 0.000 description 1
- 241000288961 Saguinus imperator Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 102100034195 Thrombopoietin Human genes 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- RBYGDVHOECIAFC-UHFFFAOYSA-L acetonitrile;palladium(2+);dichloride Chemical compound [Cl-].[Cl-].[Pd+2].CC#N.CC#N RBYGDVHOECIAFC-UHFFFAOYSA-L 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 150000005840 aryl radicals Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- GDKLLSXZTUWLJY-UHFFFAOYSA-N benzyl 5-ethyl-6-(1h-indol-6-yl)-2,4-bis(phenylmethoxy)pyridine-3-carboxylate Chemical compound C=1C=CC=CC=1COC(=O)C1=C(OCC=2C=CC=CC=2)N=C(C=2C=C3NC=CC3=CC=2)C(CC)=C1OCC1=CC=CC=C1 GDKLLSXZTUWLJY-UHFFFAOYSA-N 0.000 description 1
- WOASTEZFAISELL-UHFFFAOYSA-N benzyl 5-ethyl-6-(2-formyl-1h-indol-6-yl)-2,4-bis(phenylmethoxy)pyridine-3-carboxylate Chemical compound C=1C=CC=CC=1COC(=O)C1=C(OCC=2C=CC=CC=2)N=C(C=2C=C3NC(C=O)=CC3=CC=2)C(CC)=C1OCC1=CC=CC=C1 WOASTEZFAISELL-UHFFFAOYSA-N 0.000 description 1
- NSIDGDGEQGCRIW-UHFFFAOYSA-N benzyl 6-[2-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-1H-indol-6-yl]-5-ethyl-2,4-bis(phenylmethoxy)pyridine-3-carboxylate Chemical compound C(C1=CC=CC=C1)OC1=C(C(=O)OCC2=CC=CC=C2)C(=C(C(=N1)C1=CC=C2C=C(NC2=C1)CCO[Si](C)(C)C(C)(C)C)CC)OCC1=CC=CC=C1 NSIDGDGEQGCRIW-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000003115 checkerboard titration Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical class CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- LMEDOLJKVASKTP-UHFFFAOYSA-N dibutyl sulfate Chemical class CCCCOS(=O)(=O)OCCCC LMEDOLJKVASKTP-UHFFFAOYSA-N 0.000 description 1
- UUSPGQXHSZVVNL-UHFFFAOYSA-L dichlororuthenium;1,10-phenanthroline;hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Ru+2].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 UUSPGQXHSZVVNL-UHFFFAOYSA-L 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004460 dihydrobenzooxazinyl group Chemical group O1N(CCC2=C1C=CC=C2)* 0.000 description 1
- 125000004459 dihydrobenzooxazolyl group Chemical group O1C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005051 dihydropyrazinyl group Chemical group N1(CC=NC=C1)* 0.000 description 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 description 1
- 125000004609 dihydroquinazolinyl group Chemical group N1(CN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- JMRYOSQOYJBDOI-UHFFFAOYSA-N dilithium;di(propan-2-yl)azanide Chemical compound [Li+].CC(C)[N-]C(C)C.CC(C)N([Li])C(C)C JMRYOSQOYJBDOI-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 101150070420 gyrA gene Proteins 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- RCRODHONKLSMIF-UHFFFAOYSA-N isosuberenol Natural products O1C(=O)C=CC2=C1C=C(OC)C(CC(O)C(C)=C)=C2 RCRODHONKLSMIF-UHFFFAOYSA-N 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000005969 isothiazolinyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000005142 microbroth dilution method Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000011294 monotherapeutic Methods 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000006070 nanosuspension Substances 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000013348 organic food Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 125000005963 oxadiazolidinyl group Chemical group 0.000 description 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- SXYFKXOFMCIXQW-UHFFFAOYSA-N propanedioyl dichloride Chemical compound ClC(=O)CC(Cl)=O SXYFKXOFMCIXQW-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- UILMMYFRNCCPLK-UHFFFAOYSA-N sulfuric acid;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound OS(O)(=O)=O.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 UILMMYFRNCCPLK-UHFFFAOYSA-N 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- JBHGJHBCTKCSTH-UHFFFAOYSA-N tert-butyl 6-bromo-5-fluoroindole-1-carboxylate Chemical compound FC1=C(Br)C=C2N(C(=O)OC(C)(C)C)C=CC2=C1 JBHGJHBCTKCSTH-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- ZGNPLWZYVAFUNZ-UHFFFAOYSA-N tert-butylphosphane Chemical compound CC(C)(C)P ZGNPLWZYVAFUNZ-UHFFFAOYSA-N 0.000 description 1
- 125000005887 tetrahydrobenzofuranyl group Chemical group 0.000 description 1
- 125000005886 tetrahydrobenzothienyl group Chemical group 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000005888 tetrahydroindolyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- DGQOCLATAPFASR-UHFFFAOYSA-N tetrahydroxy-1,4-benzoquinone Chemical compound OC1=C(O)C(=O)C(O)=C(O)C1=O DGQOCLATAPFASR-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000005304 thiadiazolidinyl group Chemical group 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000005310 triazolidinyl group Chemical group N1(NNCC1)* 0.000 description 1
- 125000005881 triazolinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- VPAYJEUHKVESSD-UHFFFAOYSA-N trifluoroiodomethane Chemical compound FC(F)(F)I VPAYJEUHKVESSD-UHFFFAOYSA-N 0.000 description 1
- 229960002712 trimethoprim sulfate Drugs 0.000 description 1
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
- MHNHYTDAOYJUEZ-UHFFFAOYSA-N triphenylphosphane Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 MHNHYTDAOYJUEZ-UHFFFAOYSA-N 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical class OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present description relates to substituted 2-pyridinone compounds and forms and pharmaceutical compositions thereof and methods of using such compounds, forms or compositions thereof for treating or ameliorating Neisseria gonorrhoeae (N. gonorrhoeae). More particularly, the present description relates to bicyclic and tricyclic ring substituted 2-pyridinone compounds and forms and pharmaceutical compositions thereof and methods of using such compounds, forms or compositions thereof for treating or ameliorating a wild-type or drug-resistant form of N. gonorrhoeae.
- Neisseria is a large genus of generally commensal Gram-negative bacteria that colonize the mucosal surfaces of many animals.
- the facile ability of N. gonorrhoeae to develop drug resistance makes N. gonorrhoeae a rapidly emerging global health threat, and is considered to be an emerging superbug. 820,000 new cases of N. gonorrhoeae are estimated to occur in the United States every year. With more than 100 million cases of
- N. gonorrhoeae reported worldwide, about 12% of drug-resistant N. gonorrhoeae is estimated to be penicillin resistant (penicillin ), about 23% is estimated to be tetracycline resistant (tetracycline R ) and about 13% is estimated to be quinolone resistant (quinolone R ).
- penicillin penicillin
- tetracycline R tetracycline resistant
- quinolone R quinolone resistant
- the level of quinolone resistance in Taiwan and China is about 90% (Morbidity and
- N. gonorrhoeae Other forms of drug-resistant N. gonorrhoeae include streptomycin-resistant (streptomycin R ), ciprofloxacin-resistant (ciprofloxacin R ) and ampicillin-resistant (ampicillin ).
- streptomycin-resistant streptomycin R
- ciprofloxacin R ciprofloxacin R
- ampicillin-resistant ampicillin-resistant
- R 1; R 2 and R 3 are as defined herein, and forms and compositions thereof, and also relates to uses of a compound of Formula (I) or a form thereof and methods for treating or ameliorating Neisseria gonorrhoeae (N. gonorrhoeae) in a subject in need thereof, comprising, administering an effective amount of the compound to the subject.
- N. gonorrhoeae Neisseria gonorrhoeae
- the present description relates to a compound of Formula (I), and forms and compositions thereof, and to uses of a compound of Formula (I), and forms and compositions thereof, and methods for treating or ameliorating N. gonorrhoeae in a subject in need thereof, comprising, administering an effective amount of the compound, and forms and compositions thereof, to the subject.
- the present description also relates to a compound of Formula (I) or a form thereof having activity against wild- type or drug-resistant forms of N. gonorrhoeae.
- the present description relates to a compound of Formula (I) or a form thereof having activity against wild-type or drug-resistant forms of N. gonorrhoeae.
- the present description also relates to a compound of Formula (I) or a form thereof having activity against wild- type forms of N. gonorrhoeae.
- the present description relates to a compound of Formula (I) or a form thereof having activity against wild- type forms of N. gonorrhoeae.
- the present description also relates to a compound of Formula (I) or a form thereof having activity against drug-resistant forms of N. gonorrhoeae.
- the present description relates to a compound of Formula (I) or a form thereof having activity against drug-resistant forms of N. gonorrhoeae.
- the present description also relates to a compound of Formula (I) or a form thereof having activity against N. gonorrhoeae resistant to one or more known antibacterial or antibiotic agents, wherein drug resistance may be classified as intermediate resistance (IR), high level resistance (HLR), multi-drug resistant (MDR), multi-drug intermediate resistant (MD ⁇ R) or extensively drug resistant (XDR).
- IR intermediate resistance
- HLR high level resistance
- MDR multi-drug resistant
- MD ⁇ R multi-drug intermediate resistant
- XDR extensively drug resistant
- the present description relates to a compound of Formula (I) or a form thereof having activity against a IR, HLR, MDR, MD ⁇ R or XDR form of
- the present description also relates to a compound of Formula (I) or a form thereof having activity against an aminoglycoside-resistant, beta-lactam-resistant, cephalosporin- resistant, macrolide-resistant, quinolone-resistant or tetracycline-resistant form of
- N. gonorrhoeae The present description further relates to a compound of Formula (I) or a form thereof in combination with known agents having additive or synergistic activity, thus providing a combination product for the treatment of N. gonorrhoeae.
- the present description further relates to use of a compound of Formula (I) or a form thereof for treating or ameliorating wild- type or drug-resistant forms of N. gonorrhoeae.
- the present description relates to use of a compound of Formula (I) or a form thereof for treating or ameliorating wild- type forms of N. gonorrhoeae.
- the present description relates to use of a compound of Formula (I) or a form thereof for treating or ameliorating drug-resistant forms of N. gonorrhoeae.
- the present description also relates to use of the compound of Formula (I) or a form thereof for treating or ameliorating N. gonorrhoeae resistant to one or more known antibacterial or antibiotic agents, wherein drug resistance may be classified as intermediate resistance (IR), high level resistance (HLR), multi-drug resistant (MDR), multi-drug intermediate resistant (MD ⁇ R) or extensively drug resistant (XDR).
- IR intermediate resistance
- HLR high level resistance
- MDR multi-drug resistant
- MD ⁇ R multi-drug intermediate resistant
- XDR extensively drug resistant
- the present description relates to use of a compound of Formula (I) or a form thereof for treating or ameliorating IR, HLR, MDR, MD ⁇ R or XDR forms of N. gonorrhoeae.
- the present description also relates to use of a compound of Formula (I) or a form thereof for treating or ameliorating an aminoglycoside-resistant, beta-lactam-resistant, cephalosporin-resistant, macrolide-resistant, quinolone-resistant or tetracycline-resistant form of N. gonorrhoeae.
- the present description further relates to use of a compound of Formula (I) or a form thereof in combination with known agents having additive or synergistic activity, thus providing a combination product for the treatment of N. gonorrhoeae. DETAILED DESCRIPTION
- the present description relates to substituted 2-pyridinone compounds selected from a compound of Formula (I):
- Ri is a bicyclic or tricyclic ring system selected from the group consisting of
- R 2 is hydrogen, cyano, Ci_ 8 alkyl, hydroxyl-Ci_ 8 alkyl, formyl-Ci_ 8 alkyl, Ci-galkoxy-Ci-galkyl,
- Ci-galkoxy C 2 _galkenyl, C 2 _galkynl, carboxyl, amino-Ci_galkyl, aryl or C3_i 4 cycloalkyl;
- R 3 is hydrogen, hydroxyl, Ci_galkoxy or amino;
- R 5 is hydrogen, halogen, hydroxyl, oxo, cyano, nitro, Ci_galkyl, hydroxyl-Ci-galkyl,
- halo-Ci-galkyl Ci-galkoxy, halo-Ci-galkoxy, Ci-galkyl-thio, carboxyl, Ci-galkyl-carbonyl, Ci-galkoxy-carbonyl, amino-carbonyl, amino, Ci-galkyl-amino, (C 1 _galkyl) 2 -amino, C 2 _galkenyl- amino, (C 2 _galkenyl) 2 -amino, C 2 _galkynyl-amino, (C 2 _galkynyl) 2 -amino, amino-Ci-galkyl, Ci-ioalkyl-amino-Ci-galkyl,
- Ci-galkoxy-Ci-galkyl-amino (Ci-galkoxy-Ci-galky ⁇ Ci-galky ⁇ -amino,
- aryl-C 1 _galkyl 2 -amino-C 1 _galkyl, heteroaryl, heteroaryl-Ci-galkyl, heteroaryl-amino, heteroaryl-Ci-galkyl-amino, (heteroaryl-Ci-galky ⁇ Ci-galky ⁇ amino,
- heteroaryl-C 1 _galkyl 2 -amino
- heteroaryl-Ci-galkyl-amino-Ci-galkyl
- heteroary ⁇ Ci-galky ⁇ amino-Ci-galkyl (heteroaryl-Ci-galky ⁇ Ci-galky ⁇ amino-Ci-galkyl, heterocyclyl, heterocyclyl-Ci-galkyl, heterocyclyl-oxy, heterocyclyl-Ci-galkoxy, heterocyclyl-amino, (heterocyclyl) 2 -amino, heterocyclyl-amino-Ci-galkyl, (heterocycly ⁇ Ci-galky ⁇ amino-Ci-galkyl,
- heterocyclyl-C 1 _galkyl 2 -amino-C 1 _galkyl, heterocyclyl-oxy-amino
- R 6 is azido, halogen, hydroxyl, cyano, nitro, Ci-galkyl, halo-Ci-galkyl, hydroxyl-Ci-galkyl, Ci-galkoxy-Ci-galkyl, Ci-galkoxy, halo-Ci-galkoxy, hydroxyl-Ci-galkoxy, carboxyl, Ci-galkyl-carbonyl, Ci-galkoxy-carbonyl, amino, Ci-galkyl-amino, (C 1 _galkyl) 2 -amino, amino-Ci-galkyl-amino, (amino-Ci-galky ⁇ Ci-galky ⁇ amino,
- heteroaryl-Ci-galkyl-amino (heteroaryl-Ci-galky ⁇ Ci-galky ⁇ amino,
- heteroaryl-C 1 _galkyl 2 -amino
- heteroaryl-Ci-galkyl-amino-Ci-galkyl
- heteroaryl-C 1 -galkyl 2 -amino-C 1 _galkyl, heterocyclyl, heterocyclyl-Ci-galkyl, heterocyclyl-amino-Ci-galkyl or heterocyclyl-oxy;
- R 9 is Ci-galkyl, amino, Ci_galkyl-amino, (C 1 _galkyl) 2 -amino, amino-Ci_galkyl,
- C 3 _i 4 cycloalkyl selected in each instance, when present, from cyclopropyl, cyclobutyl,
- aryl selected in each instance, when present, from phenyl
- heteroaryl selected in each instance, when present, from pyrrolyl, thiazolyl, 1H- 1,2,3- triazolyl, lH-tetrazolyl, 2H-tetrazolyl, lH-imidazolyl or pyridinyl; and,
- heterocyclyl selected in each instance, when present, from azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, 1,4-diazepanyl, 1,3-dioxolanyl,
- Cs- ⁇ cycloalkyl selected in each instance, when present, from cyclopropyl, cyclobutyl,
- cyclopentyl cyclohexyl or cycloheptyl
- aryl selected in each instance, when present, from phenyl
- heteroaryl selected in each instance, when present, from IH-pyrrol-l-yl, thiazol-2-yl, 1H-
- heterocyclyl selected in each instance, when present, from azetidin-l-yl, tetrahydrofuran-2-yl, pyrrolidin-l-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-l-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-l-yl, piperazin-2-yl, morpholin-4-yl, 1,4- diazepan-l-yl, l,3-dioxolan-2-yl, 2,5-dihydro-lH-pyrrol-l-yl, 4,5-dihydro-lH- imidazol-2-yl, 1 ,4,5,6-tetrahydropyrimidin-2-yl, 1 ,2,3,6-tetrahydropyridin-4-yl, tetrahydro-2H-pyran-2-yl, te
- the present description further relates to a compound of Formula (I) or a form thereof, wherein:
- R 2 is hydrogen, cyano, Ci-galkyl, hydroxyl-Ci_galkyl, formyl-Ci_galkyl, Ci-galkoxy-Ci-galkyl, Ci-galkoxy, C 2 _galkenyl, C 2 _galkynl, carboxyl, amino-Ci-galkyl, aryl or C 3 -i 4 cycloalkyl;
- R 3 is hydrogen, hydroxyl, Ci-galkoxy or amino;
- R5 is hydrogen, halogen, cyano, Ci-galkyl, hydroxyl-Ci_galkyl, halo-Ci_galkyl,
- heterocyclyl is optionally substituted with one, two or three substituents each
- R9 is Ci-galkyl, amino, Ci-galkyl-amino, (Ci_galkyl) 2 -amino, amino-Ci-galkyl,
- the present description further relates to a compound of Formula (I) or a form thereof, wherein the ring system R la , and R lc is selected from a R lal , Ri b i and R lcl ring system, respectively:
- R 5a , R 5b , R 5c and R 5d when present, are selected from the group consisting of: hydrogen, halogen, hydroxyl, cyano, nitro, Ci-galkyl, hydroxyl-Ci-galkyl, halo-Ci-galkyl, Ci-galkoxy, halo-Ci-galkoxy, Ci-galkyl-thio, carboxyl, Ci-galkyl-carbonyl,
- Ci-galkoxy-Ci-galkyl-amino-Ci-galkyl Ci-galkoxy-Ci-galkyl-amino-Ci-galkyl
- C 1 _galkyl 2 -amino-carbonyl, Ci-galkyl-amino-Ci-galkyl-carbonyl, (C 1 _ 8 alkyl) 2 -amino-C 1 _ 8 alkyl-carbonyl, Cs-ncycloalkyl, Cs-ncycloalkyl-Ci-galkyl, Cs-ncycloalkyl-oxy, Cs-ncycloalkyl-Ci-galkoxy, Cs-wcycloalkyl-amino,
- aryl-C 1 -galkyl 2 -amino-C 1 _galkyl, heteroaryl, heteroaryl-Ci-galkyl, heteroaryl-amino, heteroaryl-Ci-galkyl-amino, (heteroaryl-Ci-galky ⁇ Ci-galky ⁇ amino,
- heteroaryl-C 1 _galkyl 2 -amino
- heteroaryl-Ci-galkyl-amino-Ci-galkyl
- heteroary ⁇ Ci-galky ⁇ amino-Ci-galkyl (heteroaryl-Ci-galky ⁇ Ci-galky ⁇ amino-Ci-galkyl, heterocyclyl, heterocyclyl-Ci-galkyl, heterocyclyl-oxy, heterocyclyl-Ci-galkoxy, heterocyclyl-amino, (heterocyclyl) 2 -amino, heterocyclyl-amino-Ci-galkyl, (heterocycly ⁇ Ci-galky ⁇ amino-Ci-galkyl,
- heterocyclyl-C 1 _galkyl 2 -amino-C 1 _galkyl, heterocyclyl-oxy-amino
- R 6 is azido, halogen, hydroxyl, cyano, nitro, Ci-galkyl, halo-Ci-galkyl, hydroxyl-Ci-galkyl, Ci-galkoxy-Ci-galkyl, Ci-galkoxy, halo-Ci-galkoxy, hydroxyl-Ci-galkoxy, carboxyl, Ci-galkyl-carbonyl, Ci-galkoxy-carbonyl, amino, Ci-galkyl-amino, (C 1 _galkyl) 2 -amino, amino-Ci-galkyl-amino, (amino-Ci-galky ⁇ Ci-galky ⁇ amino,
- aryl-C 1 _galkyl 2 -amino, aryl-Ci-galkyl-amino-Ci-galkyl,
- heteroaryl-Ci-galkyl-amino (heteroaryl-Ci-galky ⁇ Ci-galky ⁇ amino,
- heteroaryl-C 1 _galkyl 2 -amino
- heteroaryl-Ci-galkyl-amino-Ci-galkyl
- heteroaryl-C 1 _galkyl 2 -amino-C 1 _galkyl, heterocyclyl, heterocyclyl-Ci_galkyl, heterocyclyl-amino-Ci-galkyl or heterocyclyl-oxy;
- R 9 is Ci-galkyl, amino, Ci_galkyl-amino, (C 1 _galkyl) 2 -amino, amino-Ci_galkyl,
- the present description also relates to use of a compound of Formula (I) or a form thereof wherein R 5a , R 5 b, R 5c and R 5 d substituted on a R lal , Ribi and R lcl ring system is: C 3 _i 4 cycloalkyl selected in each instance, when present, from cyclopropyl, cyclobutyl,
- aryl selected in each instance, when present, from phenyl
- heteroaryl selected in each instance, when present, from pyrrolyl, thiazolyl, 1H- 1,2,3- triazolyl, lH-tetrazolyl, 2H-tetrazolyl, lH-imidazolyl or pyridinyl; and, heterocyclyl selected in each instance, when present, from azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, 1,4-diazepanyl, 1,3-dioxolanyl, 2,5-dihydro- IH-pyrrolyl, 4,5-dihydro- IH-imidazolyl, 1 ,4,5,6-tetrahydropyrimidinyl, 1,2,3,6-tetrahydropyridinyl, tetrahydro-2H-pyranyl, indolinyl, 2,3- dihydrobenzo[d]
- the present description also relates to use of a compound of Formula (I) or a form thereof wherein R 5a , R 5c and R 5 d substituted on a R lal , Ribi and R lcl ring system is:
- Cs-ncycloalkyl selected in each instance, when present, from cyclopropyl, cyclobutyl,
- aryl selected in each instance, when present, from phenyl
- heteroaryl selected in each instance, when present, from IH-pyrrol-l-yl, thiazol-2-yl, 1H-
- heterocyclyl selected in each instance, when present, from azetidin-l-yl, tetrahydrofuran-2-yl, pyrrolidin-l-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-l-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-l-yl, piperazin-2-yl, morpholin-4-yl, 1,4- diazepan-l-yl, l,3-dioxolan-2-yl, 2,5-dihydro-lH-pyrrol-l-yl, 4,5-dihydro-lH- imidazol-2-yl, 1 ,4,5,6-tetrahydropyrimidin-2-yl, 1 ,2,3,6-tetrahydropyridin-4-yl, tetrahydro-2H-pyran-2-yl, te
- the present description further relates to a compound of Formula (I) or a form thereof, wherein the ring system R la , R 3 ⁇ 4 and R lc is selected from the R lal , Ri b i and R lcl ring system, respectively, and R 5a , R 5b , R 5c and R 5d , when present, are selected from the group consisting of:
- Ci-ioalkyl-amino-Ci-galkyl (Ci-ioalkyl amino-Ci-galkyl,
- Ci-galkyl-amino-Ci-galkyl-carbonyl (Ci-galkyl amino-Ci-galkyl-carbonyl or heterocyclyl-Ci-galkyl;
- heterocyclyl is optionally substituted with one, two or three substituents each
- R 9 is Ci-galkyl, amino, Ci-galkyl-amino, (Ci-galkyl amino, amino-Ci-galkyl,
- a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
- the present description also relates to use of a compound of Formula (I) or a form thereof wherein Rs a , Rs , R 5c and Rsa substituted on a R lal , R ⁇ i and R lcl ring system is:
- heterocyclyl selected in each instance, when present, from pyrrolidin-l-yl.
- the present description further relates to a compound of Formula (I) or a form thereof, wherein the ring system R la , and R lc is selected from the R lal , R ⁇ i and R lcl ring system, respectively, and Rs a , Rs b , R 5c and Rsa, when present, are selected from the group consisting of (where "Ring” in the table below indicates whether an R lal , R ⁇ i or R lcl ring system is selected; and, "— " indicates that one or more of R 5a , R 5b , R 5c or R 5d are not present):
- a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
- the present description further relates to a compound of Formula (I) or a form thereof, wherein the ring system R ⁇ , Rn and R lm is selected from a Rm, Rni and R lml ring system, respectively:
- R 5a , R 5 b, R 5c , Rsa, R 5e and R5 when present are selected from the group consisting of:
- Ci-galkyl-carbonyl hydrogen, halogen, hydroxyl, cyano, nitro, Ci-galkyl, hydroxyl-Ci-galkyl, halo-Ci-galkyl, Ci- 8 alkoxy, halo-Ci-galkoxy, Ci-galkyl-thio, carboxyl, Ci-galkyl-carbonyl,
- Ci-galkoxy-Ci-galkyl-amino-Ci-galkyl Ci-galkoxy-Ci-galkyl-amino-Ci-galkyl
- aryl-C 1 -galkyl 2 -amino-C 1 _galkyl, heteroaryl, heteroaryl-Ci-galkyl, heteroaryl-amino, heteroaryl-Ci-galkyl-amino, (heteroaryl-Ci-galky ⁇ Ci-galky ⁇ amino,
- heteroaryl-C 1 _galkyl 2 -amino
- heteroaryl-Ci-galkyl-amino-Ci-galkyl
- heteroary ⁇ Ci-galky ⁇ amino-Ci-galkyl (heteroaryl-Ci-galky ⁇ Ci-galky ⁇ amino-Ci-galkyl, heterocyclyl, heterocyclyl-Ci-galkyl, heterocyclyl-oxy, heterocyclyl-Ci-galkoxy, heterocyclyl-amino, (heterocyclyl) 2 -amino, heterocyclyl-amino-Ci-galkyl, (heterocycly ⁇ Ci-galky ⁇ amino-Ci-galkyl,
- R 6 is azido, halogen, hydroxyl, cyano, nitro, Ci-galkyl, halo-Ci-galkyl, hydroxyl-Ci-galkyl, Ci-galkoxy-Ci-galkyl, Ci- 8 alkoxy, halo-Ci-galkoxy, hydroxyl-Ci-galkoxy, carboxyl, Ci-galkyl-carbonyl, Ci-galkoxy-carbonyl, amino, Ci-galkyl-amino, (C 1 _galkyl) 2 -amino, amino-Ci-galkyl-amino, (amino-Ci-galky ⁇ Ci-galky ⁇ amino,
- aryl-C 1 _galkyl 2 -amino, aryl-Ci-galkyl-amino-Ci-galkyl,
- heteroaryl-Ci-galkyl-amino (heteroaryl-Ci-galky ⁇ Ci-galky ⁇ amino,
- heteroaryl-C 1 _galkyl 2 -amino
- heteroaryl-Ci-galkyl-amino-Ci-galkyl
- heteroaryl-C 1 _galkyl 2 -amino-C 1 _galkyl, heterocyclyl, heterocyclyl-Ci-galkyl, heterocyclyl-amino-Ci-galkyl or heterocyclyl-oxy;
- R9 is Ci-galkyl, amino, Ci-galkyl-amino, (C 1 _ 8 alkyl) 2 -amino, amino-Ci-galkyl,
- the present description also relates to use of a compound of Formula (I) or a form thereof wherein R 5a , Rs c , R 5d , R 5e and R 5f substituted on a R , R 111 and R lml ring system is:
- Cs-ncycloalkyl selected in each instance, when present, from cyclopropyl, cyclobutyl,
- aryl selected in each instance, when present, from phenyl
- heteroaryl selected in each instance, when present, from pyrrolyl, thiazolyl, 1H- 1,2,3- triazolyl, lH-tetrazolyl, 2H-tetrazolyl, lH-imidazolyl or pyridinyl; and,
- heterocyclyl selected in each instance, when present, from azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, 1,4-diazepanyl, 1,3-dioxolanyl, 2,5-dihydro- lH-pyrrolyl, 4,5-dihydro- lH-imidazolyl, 1 ,4,5,6-tetrahydropyrimidinyl, 1,2,3,6-tetrahydropyridinyl, tetrahydro-2H-pyranyl, indolinyl, 2,3- dihydrobenzo[d]oxazolyl, 3,4-dihydro-2H-benzo[b][l,4]oxazinyl, 3,4- dihydroisoquinolin-(lH)-yl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,
- the present description also relates to use of a compound of Formula (I) or a form thereof wherein R 5a , R 5 b, R 5c , R 5 d, R 5e and R 5 f substituted on a R , Rin and R lml ring system is:
- Cs-ncycloalkyl selected in each instance, when present, from cyclopropyl, cyclobutyl,
- aryl selected in each instance, when present, from phenyl
- heteroaryl selected in each instance, when present, from IH-pyrrol-l-yl, thiazol-2-yl, 1H-
- heterocyclyl selected in each instance, when present, from azetidin-l-yl, tetrahydrofuran-2-yl, pyrrolidin-l-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-l-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-l-yl, piperazin-2-yl, morpholin-4-yl, 1,4- diazepan-l-yl, l,3-dioxolan-2-yl, 2,5-dihydro-lH-pyrrol-l-yl, 4,5-dihydro-lH- imidazol-2-yl, 1 ,4,5,6-tetrahydropyrimidin-2-yl, 1 ,2,3,6-tetrahydropyridin-4-yl, tetrahydro-2H-pyran-2-yl, te
- the present description further relates to a compound of Formula (I) or a form thereof, wherein the ring system Ri k , Rn and R lm is selected from the R , Rin and R lml ring system, respectively, and Rs a , Rs , R 5c , R 5d , R 5e and Rs f , when present, are selected from the group consisting of:
- the present description further relates to a compound of Formula (I) or a form thereof, wherein the ring system R ⁇ , Rn and R lm is selected from a Rm, Rni and R lml ring system, respectively, and Rs a , Rs , R 5c , R 5 d, R 5e and R5 when present, are selected from the group consisting of (where "Ring” in the table below indicates whether an Rm, Rm or R lml ring system is selected; and, "— " indicates that one or more of R 5a , R 5 b, R 5c , Rsa, R 5e or R 5 f are not present):
- a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
- the present description further relates to a compound of Formula (I) or a form thereof, wherein the ring system R ⁇ , Rn and Ry is selected from a Rm, Rm and R ⁇ ring system, respectively:
- Rs a and Rs when present, are selected from the group consisting of: hydrogen, halogen, hydroxyl, cyano, nitro, Ci-galkyl, hydroxyl-Ci-galkyl, halo-Ci-galkyl, Ci-galkoxy, halo-Ci-galkoxy, Ci-galkyl-thio, carboxyl, Ci-galkyl-carbonyl,
- Ci-galkoxy-carbonyl amino-carbonyl, amino, Ci-galkyl-amino,
- Ci-galkoxy-Ci-galkyl-amino-Ci-galkyl Ci-galkoxy-Ci-galkyl-amino-Ci-galkyl
- aryl-C 1 -galkyl 2 -amino-C 1 _galkyl, heteroaryl, heteroaryl-Ci-galkyl, heteroaryl-amino, heteroaryl-Ci-galkyl-amino, (heteroaryl-Ci-galky ⁇ Ci-galky ⁇ amino,
- heteroaryl-C 1 _galkyl 2 -amino
- heteroaryl-Ci-galkyl-amino-Ci-galkyl
- heteroary ⁇ Ci-galky ⁇ amino-Ci-galkyl (heteroaryl-Ci-galky ⁇ Ci-galky ⁇ amino-Ci-galkyl, heterocyclyl, heterocyclyl-Ci-galkyl, heterocyclyl-oxy, heterocyclyl-Ci-galkoxy, heterocyclyl-amino, (heterocyclyl) 2 -amino, heterocyclyl-amino-Ci-galkyl, (heterocycly ⁇ Ci-galky ⁇ amino-Ci-galkyl,
- heterocyclyl-C 1 -galkyl 2 -amino-C 1 _galkyl, heterocyclyl-oxy-amino
- R 6 is azido, halogen, hydroxyl, cyano, nitro, Ci-galkyl, halo-Ci-galkyl, hydroxyl-Ci-galkyl, Ci-galkoxy-Ci-galkyl, Ci-galkoxy, halo-Ci-galkoxy, hydroxyl-Ci-galkoxy, carboxyl, Ci-galkyl-carbonyl, Ci-galkoxy-carbonyl, amino, Ci-galkyl-amino, (C 1 _galkyl) 2 -amino, amino-Ci-galkyl-amino, (amino-Ci-galky ⁇ Ci-galky ⁇ amino,
- aryl-C 1 _galkyl 2 -amino, aryl-Ci-galkyl-amino-Ci-galkyl,
- heteroaryl-Ci-galkyl-amino (heteroaryl-Ci-galky ⁇ Ci-galky ⁇ amino,
- heteroaryl-C 1 _galkyl 2 -amino
- heteroaryl-Ci-galkyl-amino-Ci-galkyl
- heteroaryl-C 1 _galkyl 2 -amino-C 1 _galkyl, heterocyclyl, heterocyclyl-Ci-galkyl, heterocyclyl-amino-Ci-galkyl or heterocyclyl-oxy;
- R9 is Ci-galkyl, amino, Ci-galkyl-amino, (C 1 _galkyl) 2 -amino, amino-Ci-galkyl,
- the present description also relates to use of a compound of Formula (I) or a form thereof wherein Rs a and Rs substituted on a Rmi, Rm and R 1j1 ring system is:
- Cs-ncycloalkyl selected in each instance, when present, from cyclopropyl, cyclobutyl,
- aryl selected in each instance, when present, from phenyl
- heteroaryl selected in each instance, when present, from pyrrolyl, thiazolyl, 1H- 1,2,3- triazolyl, lH-tetrazolyl, 2H-tetrazolyl, lH-imidazolyl or pyridinyl; and,
- heterocyclyl selected in each instance, when present, from azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, 1,4-diazepanyl, 1,3-dioxolanyl, 2,5-dihydro- lH-pyrrolyl, 4,5-dihydro- lH-imidazolyl, 1 ,4,5,6-tetrahydropyrimidinyl, 1,2,3,6-tetrahydropyridinyl, tetrahydro-2H-pyranyl, indolinyl, 2,3- dihydrobenzo[d]oxazolyl, 3,4-dihydro-2H-benzo[b][l,4]oxazinyl, 3,4- dihydroisoquinolin-(lH)-yl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,
- Cs- ⁇ cycloalkyl selected in each instance, when present, from cyclopropyl, cyclobutyl,
- aryl selected in each instance, when present, from phenyl
- heteroaryl selected in each instance, when present, from IH-pyrrol-l-yl, thiazol-2-yl, 1H-
- heterocyclyl selected in each instance, when present, from azetidin-l-yl, tetrahydrofuran-2-yl, pyrrolidin-l-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-l-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-l-yl, piperazin-2-yl, morpholin-4-yl, 1,4- diazepan-l-yl, l,3-dioxolan-2-yl, 2,5-dihydro-lH-pyrrol-l-yl, 4,5-dihydro-lH- imidazol-2-yl, 1 ,4,5,6-tetrahydropyrimidin-2-yl, 1 ,2,3,6-tetrahydropyridin-4-yl, tetrahydro-2H-pyran-2-yl, te
- the present description further relates to a compound of Formula (I) or a form thereof, wherein the ring system Rm Rn and Ry is selected from the Ri h i, Rm and R 1j1 ring system, respectively, and Rs a and Rs , when present, are selected from the group consisting of:
- a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
- the present description further relates to a compound of Formula (I) or a form thereof, wherein the ring system Rm Rn and Ry is selected from the R ⁇ i, Rm and R 1j1 ring system, respectively, and Rs a and Rs , when present, are selected from the group consisting of (where "Ring” in the table below indicates whether an Rm, Rm and R ⁇ ring system is selected; and, "— " indicates that one or more of R 5a or R 5b are not present):
- a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
- the present description further relates to a compound of Formula (I) or a form thereof, wherein the ring system R 1(1 , Ri e , Ri f and R lg is selected from a R 1( JI, R le i, Rin and R lgl ring system, respectively:
- Rs a , Rs t ,, R 5c and Rsa when present, are selected from the group consisting of: hydrogen, halogen, hydroxyl, , cyano, nitro, Ci-galkyl, hydroxyl-Ci-galkyl, halo-Ci-galkyl, Ci- 8 alkoxy, halo-Ci-galkoxy, Ci-galkyl-thio, carboxyl, Ci-galkyl-carbonyl,
- Ci-galkoxy-Ci-galkyl-amino-Ci-galkyl Ci-galkoxy-Ci-galkyl-amino-Ci-galkyl
- aryl-C 1 -galkyl 2 -amino-C 1 _galkyl, heteroaryl, heteroaryl-Ci-galkyl, heteroaryl-amino, heteroaryl-Ci-galkyl-amino, (heteroaryl-Ci-galky ⁇ Ci-galky ⁇ amino,
- heteroaryl-C 1 _galkyl 2 -amino
- heteroaryl-Ci-galkyl-amino-Ci-galkyl
- heteroary ⁇ Ci-galky ⁇ amino-Ci-galkyl (heteroaryl-Ci-galky ⁇ Ci-galky ⁇ amino-Ci-galkyl, heterocyclyl, heterocyclyl-Ci-galkyl, heterocyclyl-oxy, heterocyclyl-Ci-galkoxy, heterocyclyl-amino, (heterocyclyl) 2 -amino, heterocyclyl-amino-Ci-galkyl, (heterocycly ⁇ Ci-galky ⁇ amino-Ci-galkyl,
- R 6 is azido, halogen, hydroxyl, cyano, nitro, Ci-galkyl, halo-Ci-galkyl, hydroxyl-Ci-galkyl, Ci-galkoxy-Ci-galkyl, Ci- 8 alkoxy, halo-Ci-galkoxy, hydroxyl-Ci-galkoxy, carboxyl, Ci-galkyl-carbonyl, Ci-galkoxy-carbonyl, amino, Ci-galkyl-amino, (C 1 _galkyl) 2 -amino, amino-Ci-galkyl-amino, (amino-Ci-galky ⁇ Ci-galky ⁇ amino,
- aryl-C 1 _galkyl 2 -amino, aryl-Ci-galkyl-amino-Ci-galkyl,
- heteroaryl-Ci-galkyl-amino (heteroaryl-Ci-galky ⁇ Ci-galky ⁇ amino,
- heteroaryl-C 1 _galkyl 2 -amino
- heteroaryl-Ci-galkyl-amino-Ci-galkyl
- heteroaryl-C 1 _galkyl 2 -amino-C 1 _galkyl, heterocyclyl, heterocyclyl-Ci-galkyl, heterocyclyl-amino-Ci-galkyl or heterocyclyl-oxy;
- R9 is Ci-galkyl, amino, Ci-galkyl-amino, (C 1 _ 8 alkyl) 2 -amino, amino-Ci-galkyl,
- the present description also relates to use of a compound of Formula (I) or a form thereof wherein R 5a , R 5c and R 5d substituted on a R 1( JI, R le i, Rin and R lgl ring system is: Cs- ⁇ cycloalkyl selected in each instance, when present, from cyclopropyl, cyclobutyl,
- aryl selected in each instance, when present, from phenyl
- heteroaryl selected in each instance, when present, from pyrrolyl, thiazolyl, 1H- 1,2,3- triazolyl, lH-tetrazolyl, 2H-tetrazolyl, lH-imidazolyl or pyridinyl; and,
- heterocyclyl selected in each instance, when present, from azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, 1,4-diazepanyl, 1,3-dioxolanyl, 2,5-dihydro- lH-pyrrolyl, 4,5-dihydro- lH-imidazolyl, 1 ,4,5,6-tetrahydropyrimidinyl, 1,2,3,6-tetrahydropyridinyl, tetrahydro-2H-pyranyl, indolinyl, 2,3- dihydrobenzo[d]oxazolyl, 3,4-dihydro-2H-benzo[b] [l,4]oxazinyl, 3,4- dihydroisoquinolin-(lH)-yl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,
- the present description also relates to use of a compound of Formula (I) or a form thereof wherein R 5a , R 5b , R 5c and R 5d substituted on a R 1( JI, R le i, Rin and R lgl ring system is: Cs- ⁇ cycloalkyl selected in each instance, when present, from cyclopropyl, cyclobutyl,
- aryl selected in each instance, when present, from phenyl
- heteroaryl selected in each instance, when present, from IH-pyrrol- l-yl, thiazol-2-yl, 1H-
- heterocyclyl selected in each instance, when present, from azetidin- l-yl, tetrahydrofuran-2-yl, pyrrolidin-l-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-l-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin- l-yl, piperazin-2-yl, morpholin-4-yl, 1,4- diazepan- l-yl, l,3-dioxolan-2-yl, 2,5-dihydro-lH-pyrrol- l-yl, 4,5-dihydro- lH- imidazol-2-yl, 1 ,4,5,6-tetrahydropyrimidin-2-yl, 1 ,2,3,6-tetrahydropyridin-4-yl, tetrahydro-2H-pyran-2-y
- the present description further relates to a compound of Formula (I) or a form thereof, wherein the ring system R 1(1 , Ri e , Ri f and R lg is selected from the R 1( JI, Ri e i, Rin and R lgl ring system, respectively, and R 5a , R 5b , R 5c and R 5d , when present, are selected from the group consisting of:
- a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
- the present description further relates to a compound of Formula (I) or a form thereof, wherein the ring system R 1(1 , Ri e , Ri f and R lg is selected from the R 1( JI, Riei , Rin and R lgl ring system, respectively, and R 5a , R 5 b, R 5c and R 5 d, when present, are selected from the group consisting of (where "Ring” in the table below indicates whether an R 1( JI, R le i, Rin or R lgl ring system is selected; and, "— " indicates that one or more of Rs a , Rs , R 5c or Rsa are not present):
- a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
- the compound of Formula (I) or a form thereof is selected from the group consisting of:
- a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
- the compound of Formula (I) or a form thereof (wherein compound number (#*) indicates that the salt form was isolated) is selected from the group consisting of:
- 53 5-amino-4-hydroxy-6-(l-methyl-lH-indol-5-yl)-2-oxo-l,2-dihydropyridine-3- carboxylic acid; wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
- the compound or a form thereof is isolated as a salt.
- the present description includes a method of use for treating or ameliorating wild-type or drug-resistant forms of N. gonorrhoeae in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof to the subject.
- An embodiment of the use of a compound of Formula (I) or a form thereof includes a method of use for a compound or a form thereof for treating or ameliorating wild-type or drug-resistant forms of N. gonorrhoeae in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof (wherein compound number (#*) indicates that the salt form was isolated) to the subject, selected from the group consisting of:
- 53 5-amino-4-hydroxy-6-(l-methyl-lH-indol-5-yl)-2-oxo-l,2-dihydropyridine-3- carboxylic acid; wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
- Another embodiment of the use of a compound of Formula (I) or a form thereof includes a method of use for a compound salt or a form thereof for treating or ameliorating wild-type or drug-resistant forms of N. gonorrhoeae in a subject in need thereof, comprising administering an effective amount of the compound salt of Formula (I) or a form thereof to the subject, selected from the group consisting of:
- the present description includes a method of use for treating or ameliorating wild-type or drug-resistant forms of N. gonorrhoeae in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof to the subject.
- the present description includes a method of use for treating or ameliorating wild-type or drug-resistant forms of N. gonorrhoeae in a subject in need thereof, comprising administering an effective amount of the compound salt of Formula (I) or a form thereof to the subject.
- the compound salt or a form thereof is isolated for use.
- Ci-ioalkyl generally refers to saturated hydrocarbon radicals having from one to ten carbon atoms in a straight or branched chain configuration, including, without limitation, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl and the like.
- Ci-ioalkyl includes Ci-galkyl, Ci_ 6 alkyl, C 1 _ 4 alkyl and the like.
- a Ci-ioalkyl radical may be optionally substituted where allowed by available valences.
- C 2 -galkenyl generally refers to partially unsaturated hydrocarbon radicals having from two to eight carbon atoms in a straight or branched chain configuration and one or more carbon-carbon double bonds therein, including, without limitation, ethenyl, allyl, propenyl and the like.
- C 2 -galkenyl includes C 2 - 6 alkenyl, C 2 - 4 alkenyl and the like.
- a C 2 -galkenyl radical may be optionally substituted where allowed by available valences.
- C 2 - 8 alkynyl generally refers to partially unsaturated hydrocarbon radicals having from two to eight carbon atoms in a straight or branched chain configuration and one or more carbon-carbon triple bonds therein, including, without limitation, ethynyl, propynyl and the like.
- C 2 -galkynyl includes C 2 - 6 alkynyl, C 2 - 4 alkynyl and the like.
- a C 2 - 8 alkynyl radical may be optionally substituted where allowed by available valences.
- Ci-salkoxy generally refers to saturated hydrocarbon radicals having from one to eight carbon atoms in a straight or branched chain configuration of the formula: -O-Ci-galkyl, including, without limitation, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, n-hexoxy and the like.
- Ci-salkoxy includes Ci ⁇ alkoxy, Ci_ 4 alkoxy and the like.
- a Ci-salkoxy radical may be optionally substituted where allowed by available valences.
- C 3 _i 4 cycloalkyl generally refers to a saturated monocyclic, bicyclic or polycyclic hydrocarbon radical, including, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, lH-indanyl, indenyl, tetrahydro-naphthalenyl and the like.
- C 3 _ 14 cycloalkyl includes C 3 _gcycloalkyl, Cs-gcycloalkyl, C 3 _iocycloalkyl and the like.
- a C3_ 14 cycloalkyl radical may be optionally substituted where allowed by available valences.
- aryl generally refers to a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure radical, including, without limitation, phenyl, naphthyl, anthracenyl, fluorenyl, azulenyl, phenanthrenyl and the like.
- An aryl radical may be optionally substituted where allowed by available valences.
- heteroaryl generally refers to a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure radical in which one or more carbon atom ring members have been replaced, where allowed by structural stability, with one or more heteroatoms, such as an O, S or N atom, including, without limitation, furanyl, thienyl (also referred to as thiophenyl), pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyranyl, thiopyranyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, indolyl, indazolyl, indolizinyl, benzofuranyl, benzothi
- heterocyclyl generally refers to a saturated or partially unsaturated monocyclic, bicyclic or polycyclic carbon atom ring structure radical in which one or more carbon atom ring members have been replaced, where allowed by structural stability, with a heteroatom, such as an O, S or N atom, including, without limitation, oxiranyl, oxetanyl, azetidinyl, dihydrofuranyl, tetrahydrofuranyl, dihydrothienyl,
- dihydro-triazinyl dihydro-triazinyl, tetrahydro-triazinyl, hexahydro-triazinyl, 1,4-diazepanyl, dihydro-indolyl, indolinyl, tetrahydro-indolyl, dihydro-indazolyl, tetrahydro-indazolyl, dihydro-isoindolyl, dihydro-benzofuranyl, tetrahydro-benzofuranyl, dihydro-benzothienyl,
- C 2 - 8 alkenyl-amino refers to a radical of the formula:
- (C 2 - 8 alkenyl) 2 -amino refers to a radical of the formula: -N(C 2 _ 8 alkenyl) 2 .
- the term refers to a radical of the formula: -Ci-salkyl-NH-C ⁇ alkenyl.
- the term ' C 2 - 8 alkenyl) 2 -amino-C 1 _ 8 alkyr refers to a radical of the formula: -C 1 _ 8 alkyl-N(C 2 - 8 alkenyl) 2 .
- Ci-salkoxy-Ci-salkyl refers to a radical of the formula: -Ci-galkyl-O-Ci-galkyl.
- Ci-galkoxy-Ci-galkyl-amino refers to a radical of the formula: -O-Ci.galkyl-NH-C ⁇ alkyl-O-C ⁇ alkyl.
- (C 1 _galkoxy-C 1 _galkyl) 2 -amino refers to a radical of the formula: -N(C 1 _galkyl-0-C 1 -galkyl) 2 .
- Ci-galkoxy-Ci-galkyl-amino-Ci-galkyl refers to a radical of the formula: -Ci.galkyl-NH-C ⁇ alkyl-O-Ci.galkyl.
- (C 1 _galkoxy-C 1 -galkyl) 2 -amino-C 1 -galkyl refers to a radical of the formula: -C 1 -galkyl-N(C 1 - 8 alkyl-0-C 1 -galkyl) 2 .
- (Ci-galkoxy-Ci-galky ⁇ Ci-galky ⁇ -amino) refers to a radical of the formula: -NK ⁇ galkylX ⁇ galkyl-O-Ci.galkyl)].
- (Ci-galkoxy-Ci-galky ⁇ Ci-galky ⁇ -amino-Ci-galkyl) refers to a radical of the formula: -Ci-galkyl-NfCCi-galky CCi-galkyl-O-Ci-galkyl)].
- Ci-galkoxy-carbonyl refers to a radical of the formula: -C(0)-0-Ci_ 8 alkyl.
- Ci-galkyl-amino refers to a radical of the formula:
- (C 1 _galkyl) 2 -amino refers to a radical of the formula:
- Ci-galkyl-amino-Ci-galkyl refers to a radical of the formula: -Ci-galkyl-NH-Ci-galkyl.
- Ci-ioalkyl-amino-Ci-galkyl refers to a radical of the formula: -Ci.galkyl-NH-C oalkyl.
- (C 1 _ 1 oalkyl) 2 -amino-C 1 -galkyl refers to a radical of the formula: -C 1 _galkyl-N(C 1 _ 1 oalkyl) 2 .
- Ci-galkyl-amino-Ci-galkyl-amino refers to a radical of the formula: -NH-Ci.galkyl-NH-Ci.galkyl.
- (C 1 -galkyl) 2 -amino-C 1 _galkyl-amino refers to a radical of the formula: -NH-C 1 - 8 alkyl-N(C 1 -galkyl) 2 .
- the term "Ci-galkyl-amino-Ci-galkyl-amino-Ci-galkyl” refers to a radical of the formula: -C 1-8 alkyl-NH-C 1-8 alkyl-NH-C 1-8 alkyl.
- (Ci-salky ⁇ i-amino-Ci-salkyl-amino-Ci-salkyl refers to a radical of the formula: -C 1-8 alkyl-NH-C 1-8 alkyl-N(C 1-8 alkyl) 2 .
- (Ci-salkyl-amino-Ci-salky ⁇ Ci-salky ⁇ amino refers to a radical of the formula: -NKC ⁇ alkylXCi.galkyl-NH-C ⁇ alkyl)].
- (Ci-galkyl-amino-Ci-galky ⁇ Ci-galky ⁇ amino-Ci-galkyl) refers to a radical of the formula: -Ci- 8 alkyl-N[(Ci- 8 alkyl)(Ci- 8 alkyl-NH-Ci- 8 alkyl)] .
- [(C 1-8 alkyl) 2 -aiidno-C 1-8 alkyl,C 1-8 alkyl]amino-C 1-8 alky ' refers to a radical of the formula: -C 1-8 alkyl-N ⁇ (C 1-8 alkyl)[C 1-8 alkyl-N(C 1-8 alkyl) 2 ] ⁇ .
- (C 1 _ 8 alkyl-amino-C 1 _ 8 alkyl) 2 -amino-C 1 _ 8 alkyl refers to a radical of the formula: -C 1 _ 8 alkyl-N(C 1 _ 8 alkyl-NH-C 1 _ 8 alkyl) 2 .
- Ci-salkyl-amino-carbonyl refers to a radical of the formula:
- (C 1 _galkyl) 2 -amino-carbonyl refers to a radical of the formula: -C(0)-N(C 1 _ 8 alkyl) 2 .
- C ⁇ alkyl-amino-C ⁇ alkyl-carbonyr refers to a radical of the formula: -C(0)-C 1 - 8 alkyl-NH-C 1 _ 8 alkyl.
- (C 1 _ 8 alkyl) 2 -amino-C 1 _ 8 alkyl-carbonyl refers to a radical of the formula: -C(0)-C 1 _ 8 alkyl-N(C 1 _ 8 alkyl) 2 .
- Ci-salkyl-carbonyl refers to a radical of the formula:
- Ci-salkyl-carbonyl-amino refers to a radical of the formula:
- (Ci-salkyl-carbony ⁇ Ci-salky ⁇ amino-Ci-salkyl) refers to a radical of the formula: -C 1 - 8 alkyl-N[(C 1 _ 8 alkyl)(-C(0)-C 1 - 8 alkyl)].
- Ci-salkyl-thio refers to a radical of the formula:
- C ⁇ salkynyl-Ci-salkyl refers to a radical of the formula: -Ci-salkyl-C ⁇ salkynyl.
- C 2 _galkynyl- amino refers to a radical of the formula:
- (C 2 - 8 alkynyl) 2 -amino refers to a radical of the formula: -N(C 2 -8alkynyl) 2 .
- the term refers to a radical of the formula: -C 1 _ 8 alkyl-NH-C 2 - 8 alkynyl.
- (C 2 - 8 alkynyl) 2 -amino-C 1 - 8 alkyl refers to a radical of the formula: -C 1 _8alkyl-N(C 2 -8alkynyl) 2 .
- amino refers to a radical of the formula: -NH 2 .
- amino-Ci-galkyl refers to a radical of the formula:
- amino-Ci-galkyl-amino refers to a radical of the formula: -NH-C 1 _ 8 alkyl-NH 2 .
- (amino-C 1 _galkyl) 2 -amino) refers to a radical of the formula: -N(C 1 _ 8 alkyl-NH 2 ) 2 .
- amino-C 1 _ 8 alkyl refers to a radical of the formula: -C 1 _ 8 alkyl-N(C 1 _ 8 alkyl-NH 2 ) 2 .
- amino-Ci-galkyl-amino-Ci-galkyl refers to a radical of the formula: -C 1 - 8 alkyl-NH-C 1 - 8 alkyl-NH 2 .
- amino- ⁇ galky ⁇ Ci-galky ⁇ amino refers to a radical of the formula: -N[(C 1 _ 8 alkyl)(C 1 _ 8 alkyl-NH 2 )] .
- amino-Ci-galky ⁇ Ci-galky ⁇ amino-Ci-galkyl refers to a radical of the formula: -C 1 - 8 alkyl-N[(C 1 - 8 alkyl)(C 1 - 8 alkyl-NH 2 )].
- amino-carbonyl refers to a radical of the formula:
- aryl-Ci-galkoxy refers to a radical of the formula:
- aryl- ⁇ galkoxy-carbonyl-amino refers to a radical of the formula: -NH-C(0)-0-C 1 _ 8 alkyl-aryl.
- aryl-Ci-galkyl refers to a radical of the formula:
- the term refers to a radical of the formula: -NH-Ci-galkyl-aryl.
- (aryl-C 1 _ 8 alkyl) 2 -amino refers to a radical of the formula: -NtCd-galkyl-aryDJ.
- aryl- ⁇ galkyl-amino-Ci-galkyl refers to a radical of the formula: - ⁇ galkyl-NH-Ci-galkyl-aryl.
- (aryl-C 1 _ 8 alkyl) 2 -amino-C 1 _ 8 alkyl refers to a radical of the formula: -C 1 _ 8 alkyl-N[(C 1 _galkyl-aryl) 2 ].
- the term refers to a radical of the formula: -N[(Ci_ 8 alkyl)(aryl)] .
- ary ⁇ Ci-galky ⁇ amino-Ci-galkyl refers to a radical of the formula: -Ci. 8 alkyl-N[(Ci- 8 alkyl)(aryl)].
- the term refers to a radical of the formula: -N[(Ci- 8 alkyl)(Ci- 8 alkyl-aryl)] .
- aryl-Ci-galky ⁇ Ci-galky ⁇ amino-Ci-galkyl refers to a radical of the formula: -Ci- 8 alkyl-N[(Ci- 8 alkyl)(Ci- 8 alkyl-aryl)].
- aryl-amino refers to a radical of the formula: -NH-aryl.
- (aryl) 2 -amino refers to a radical of the formula: -N[(aryl) 2 ].
- aryl-amino-Ci-galkyl refers to a radical of the formula: -Ci-galkyl-NH-aryl.
- (aryl) 2 -amino-C 1 _galkyl refers to a radical of the formula: -Ci. 8 alkyl-N[(aryl) 2 ].
- aryl-amino-carbonyl refers to a radical of the formula: -C(0)-NH-aryl.
- carboxyl refers to a radical of the formula: -COOH, -C(0)OH or -C0 2 H.
- (carboxyl-Ci-galky ⁇ Ci-galky ⁇ amino-carbonyl-amino refers to a radical of the formula: -NH-C(0)-N[(C 1 _galkyl)(C 1 -galkyl-C0 2 H)].
- Cs-wcycloalkyl-Ci-galkoxy refers to a radical of the formula:
- Cs- ⁇ cycloalkyl-amino refers to a radical of the formula: -NH-C 3-14 cycloalkyl.
- Cs- H cycloalkyl-amino-Ci-galkyl refers to a radical of the formula: -Ci-galkyl-NH-Cs-wcycloalkyl.
- (Cs- M cycloalkyl amino-Ci-galkyl) refers to a radical of the formula: - ⁇ galkyl-N[(C 3 -i 4 cycloalkyl) 2 ] .
- Cs- H cycloalkyl-Ci-galkyl-amino-Ci-galkyl refers to a radical of the formula: -Ci-galkyl-NH-Ci-galkyl-Cs- H cycloalkyl.
- (Cs- M cycloalkyl-Ci-galkyl amino-Ci-galkyl refers to a radical of the formula: -Ci-galkyl-N ⁇ galkyl-Cs-wcycloalkyl) ⁇ .
- (Cs- H cycloalky ⁇ Ci-galky ⁇ amino-Ci-galkyl) refers to a radical of the formula: -Ci-galkyl-N Ci-galkylXCs- H cycloalkyl)].
- (Cs-wcycloalkyl-Ci-galky ⁇ Ci-galky ⁇ amino-Ci-galkyl) refers to a radical of the formula: -Ci-galkyl-NfiCi-galky ⁇ iCi-galkyl-Cs- ⁇ cycloalkyl)].
- C 3 _i 4 cycloalkyl-oxy refers to a radical of the formula: -O-Cs-ncycloalkyl.
- halo or halogen generally refers to a halogen atom radical, including fluoro, chloro, bromo and iodo.
- halo-Ci-galkoxy refers to a radical of the formula:
- halo-Ci-galkoxy includes halo-C i ⁇ alkoxy, halo-Ci ⁇ alkoxy and the like.
- halo-Ci-galkyl refers to a radical of the formula:
- halo-Ci-galkyl includes halo-Ci_ 6 alkyl, halo-C i ⁇ alkyl and the like.
- halo-Ci-galkyl-amino refers to a radical of the formula: -NH-Ci-galkyl-halo.
- halo-Ci-galkyl ⁇ -amino refers to a radical of the formula:
- halo-Ci-galkyl-amino-Ci-galkyl refers to a radical of the formula: -NH-Ci_galkyl-halo.
- (halo-C 1 _ 8 alkyl) 2 -amino-C 1 _ 8 alkyl refers to a radical of the formula: -C 1 _ 8 alkyl-N(C 1 _galkyl-halo) 2 .
- heteroaryl-Ci-galkyl refers to a radical of the formula: -Ci-galkyl-heteroaryl.
- heteroaryl- amino refers to a radical of the formula:
- (heteroaryl) 2 -amino refers to a radical of the formula: -N[(heteroaryl) 2 ].
- heteroaryl-Ci-galkyl-amino refers to a radical of the formula: -NH-Ci-galkyl-heteroaryl.
- heteroaryl-C 1 _ 8 alkyl) 2 -amino refers to a radical of the formula: -N[(C 1 _ 8 alkyl-heteroaryl) 2 ] .
- heteroaryl-Ci-galkyl-amino-Ci-galkyl refers to a radical of the formula: -Ci-galkyl-NH-Ci-galkyl-heteroaryl.
- heteroaryl-C 1 -galkyl) 2 -amino-C 1 _galkyl refers to a radical of the formula: -C 1 _galkyl-N[(C 1 _galkyl-heteroaryl) 2 ].
- heteroaryl-Ci-galky ⁇ Ci-galky ⁇ amino refers to a radical of the formula: -N Ci-galkylXCi-galkyl-heteroaryl)].
- heteroary ⁇ Ci-galky ⁇ amino-Ci-galkyl refers to a radical of the formula: -Ci- 8 alkyl-N[(Ci- 8 alkyl)(heteroaryl)].
- heteroaryl-Ci-galky ⁇ Ci-galky ⁇ amino-Ci-galkyl refers to a radical of the formula: -Ci-galkyl-N Ci-galkylXCi-galkyl -heteroaryl)].
- heterocyclyl-Ci-galkoxy refers to a radical of the formula: -O-Ci-galkyl-heterocyclyl.
- heterocyclyl-Ci-galkyl refers to a radical of the formula:
- heterocyclyl-amino refers to a radical of the formula: -NH-heterocyclyl.
- (heterocyclyl) 2 -amino refers to a radical of the formula: -N[(heterocyclyl) 2 ].
- heterocyclyl-amino-Ci-galkyl refers to a radical of the formula: -Ci-galkyl-NH-heterocyclyl.
- (heterocyclyl) 2 -amino-C 1 _ 8 alkyl refers to a radical of the formula: -C 1 _galkyl-N[(heterocyclyl) 2 ] .
- heterocyclyl-Ci-salkyl-amino-C ⁇ alkyl refers to a radical of the formula: -Ci-salkyl-NH-C ⁇ alkyl-heterocyclyl.
- heterocyclyl-C 1 _ 8 alkyl) 2 -amino-C 1 _galkyl refers to a radical of the formula: -C 1 _ 8 alkyl-N[(C 1 _galkyl-heterocyclyl) 2 ].
- heterocyclyl,C ⁇ alkyl)amino refers to a radical of the formula: -NIXCi-salkylXheterocyclyl)] .
- heterocycly ⁇ Ci-galky ⁇ amino-Ci-galkyl refers to a radical of the formula: -C 1-8 alkyl-N[(C 1-8 alkyl)(heterocyclyl)].
- heterocyclyl-Ci-salky ⁇ Ci-salky ⁇ amino-Ci-salkyl refers to a radical of the formula: -C ⁇ alkyl-N Ci-salkylXC ⁇ alkyl-heterocyclyl)].
- heterocycly ⁇ Cs- H cycloalkyl-Ci-salky ⁇ amino-Ci-salkyl refers to a radical of the formula: -Ci-salkyl-Nfiheterocycly ⁇ iCi-salkyl-Cs-wcycloalkyl)].
- heterocyclyl-carbonyl refers to a radical of the formula:
- heterocyclyl-carbonyl-oxy refers to a radical of the formula: -0-C(0)-heterocyclyl.
- heterocyclyl-oxy refers to a radical of the formula:
- heterocyclyl-oxy-amino refers to a radical of the formula: -NH-O-heterocyclyl.
- heterocyclyl-oxy) 2 -amino refers to a radical of the formula: -N[(-0-heterocyclyl) 2 ].
- heterocyclyl-oxy ⁇ i-salky ⁇ amino refers to a radical of the formula: -N[(C 1-8 alkyl)(-0-heterocyclyl)] .
- heterocyclyl-oxy-Ci-salky ⁇ C ⁇ alky ⁇ amino refers to a radical of the formula: -N C ⁇ alkylXCi-salkyl-O-heterocyclyl)].
- hydroxyl-Ci-salkoxy refers to a radical of the formula: -O-Ci-salkyl-OH, wherein Ci-salkyl may be partially or completely substituted where allowed by available valences with one or more hydroxyl radicals.
- ''hydroxyl-Ci-galkyl'' refers to a radical of the formula:
- Ci_galkyl may be partially or completely substituted where allowed by available valences with one or more hydroxy radicals.
- hydroxyl-Ci-salkyl-amino refers to a radical of the formula: -NH-Ci-galkyl-OH, wherein Ci-galkyl may be partially or completely substituted where allowed by available valences with one or more hydroxyl radicals.
- hydroxyl-Ci-galkyl amino refers to a radical of the formula: -N(Ci-galkyl-OH)2, wherein Ci-galkyl may be partially or completely substituted where allowed by available valences with one or more hydroxyl radicals.
- '3 ⁇ 4ydroxyl-Ci_galkyl-amino-Ci_galkyr refers to a radical of the formula: -Ci-galkyl-NH-Ci-galkyl-OH, wherein Ci-galkyl may be partially or completely substituted where allowed by available valences with one or more hydroxyl radicals.
- hydroxyl-Ci-galkyl-amino-Ci-galkyl-amino refers to a radical of the formula: -NH-Ci-galkyl-NH-Ci-galkyl-OH, wherein Ci-galkyl may be partially or completely substituted where allowed by available valences with one or more hydroxyl radicals.
- hydroxyl-Ci_galkyl,Ci_galkyl)amino refers to a radical of the formula: -N ⁇ Ci-galkylXCi-galkyl-OH)], wherein Ci-galkyl may be partially or completely substituted where allowed by available valences with one or more hydroxyl radicals.
- hydroxyl-Ci-galkyl,Ci-galkyl)amino-Ci-galkyl refers to a radical of the formula: -Ci-galkyl-N Ci-galkylXCi-galkyl-OH)], wherein Ci-galkyl may be partially or completely substituted where allowed by available valences with one or more hydroxyl radicals.
- Ci-galkylXCi-galkyl-OH N Ci-galkylXCi-galkyl-OH] ⁇ ], wherein Ci-galkyl may be partially or completely substituted where allowed by available valences with one or more hydroxyl radicals.
- hydroxyl-Ci-galkyl-amino-Ci-galkyl,Ci_galkyl)amino refers to a radical of the formula: -N Ci-galkylXCi-galkyl-NH-Ci-galkyl-OH)], wherein Ci-galkyl may be partially or completely substituted where allowed by available valences with one or more hydroxyl radicals.
- substituted means positional variables on the atoms of a core molecule that are substituted at a designated atom position, replacing one or more hydrogens on the designated atom, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
- any carbon as well as heteroatom with valences that appear to be unsatisfied as described or shown herein is assumed to have a sufficient number of hydrogen atom(s) to satisfy the valences described or shown.
- the term "and the like,” with reference to the definitions of chemical terms provided herein, means that variations in chemical structures that could be expected by one skilled in the art include, without limitation, isomers (including chain, branching or positional structural isomers), hydration of ring systems (including saturation or partial unsaturation of monocyclic, bicyclic or polycyclic ring structures) and all other variations where allowed by available valences which result in a stable compound.
- each functionality appearing at any location within the disclosed compound may be independently selected, and as appropriate, independently and/or optionally substituted.
- the pattern of substitution at each occurrence is independent of the pattern at any other occurrence.
- a generic substituent variable on any formula or structure for a compound described herein is understood to include the replacement of the generic substituent with species substituents that are included within the particular genus, e.g. , aryl may be replaced with phenyl or naphthalenyl and the like, and that the resulting compound is to be included within the scope of the compounds described herein.
- each instance of or “in each instance, when present,” when used preceding a phrase such as "...Cs-ncycloalkyl, Cs-ncycloalkyl-Ci-galkyl, aryl, aryl-Ci-galkyl, heteroaryl, heteroaryl-Ci-galkyl, heterocyclyl and heterocyclyl-Ci-galkyl,” are intended to refer to the Cs- ⁇ cycloalkyl, aryl, heteroaryl and heterocyclyl ring systems when each are present either alone or as a substituent.
- stable compound' or stable structure mean a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture and formulations thereof into an efficacious therapeutic agent.
- form means a compound of Formula (I) having a form selected from the group consisting of a free acid, free base, prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
- the form of the compound of Formula (I) is a free acid, free base or salt thereof.
- the form of the compound of Formula (I) is a salt thereof.
- the form of the compound of Formula (I) is an isotopologue thereof.
- the form of the compound of Formula (I) is a stereoisomer, racemate, enantiomer or diastereomer thereof.
- the form of the compound of Formula (I) is a tautomer thereof.
- the form of the compound of Formula (I) is a pharmaceutically acceptable form.
- the compound of Formula (I) or a form thereof is isolated for use.
- isolated means the physical state of a compound of Formula (I) or a form thereof after being isolated and/or purified from a synthetic process (e.g., from a reaction mixture) or natural source or combination thereof according to an isolation or purification process or processes described herein or which are well known to the skilled artisan (e.g., chromatography, recrystallization and the like) in sufficient purity to be characterizable by standard analytical techniques described herein or well known to the skilled artisan.
- protected means that a functional group in a compound of Formula (I) or a form thereof is in a form modified to preclude undesired side reactions at the protected site when the compound is subjected to a reaction.
- Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T.W. Greene et al, Protective Groups in organic Synthesis (1991), Wiley, New York.
- Prodrugs and solvates of the compounds described herein are also contemplated.
- the term "prodrug” means a form of an instant compound (e.g., a drug precursor) that is transformed in vivo to yield an active compound of Formula (I) or a form thereof. The transformation may occur by various mechanisms (e.g., by metabolic and/or non-metabolic chemical processes), such as, for example, by hydrolysis and/or metabolism in blood, liver and/or other organs and tissues.
- a discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
- a prodrug when a compound of Formula (I) or a form thereof contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a functional group such as alkyl and the like.
- a prodrug form when a compound of Formula (I) or a form thereof contains a hydroxyl functional group, a prodrug form can be prepared by replacing the hydrogen atom of the hydroxyl with another functional group such as alkyl, alkylcarbonyl or a phosphonate ester and the like.
- a prodrug form when a compound of Formula (I) or a form thereof contains an amine functional group, a prodrug form can be prepared by replacing one or more amine hydrogen atoms with a functional group such as alkyl or substituted carbonyl.
- prodrugs of compounds of Formula (I) or a form thereof include those compounds substituted with one or more of the following groups: carboxylic acid esters, sulfonate esters, amino acid esters, phosphonate esters and mono-, di- or triphosphate esters or alkyl substituents, where appropriate. As described herein, it is understood by a person of ordinary skill in the art that one or more of such substituents may be used to provide a compound of Formula (I) or a form thereof as a prodrug.
- One or more compounds described herein may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and the description herein is intended to embrace both solvated and unsolvated forms.
- solvate means a physical association of a compound described herein with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. As used herein, “solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like.
- One or more compounds described herein may optionally be converted to a solvate.
- solvates Preparation of solvates is generally known.
- the preparation of solvates of the antifungal fluconazole in ethyl acetate as well as from water has been described (see, M. Caira et al, J. Pharmaceutical Sci., 93(3), 601-611 (2004)). Similar preparations of solvates, hemisolvate, hydrates and the like have also been described (see, E.C. van Tonder et al, AAPS
- a typical, non-limiting process involves dissolving a compound in a desired amount of the desired solvent (organic or water or mixtures thereof) at a higher than ambient temperature, and cooling the solution at a rate sufficient to form crystals which are then isolated by standard methods.
- Analytical techniques such as, for example infrared spectroscopy, show the presence of the solvent (or water) in the crystals as a solvate (or hydrate).
- hydrate means a solvate wherein the solvent molecule is water.
- the compounds of Formula (I) can form salts, which are intended to be included within the scope of this description.
- Reference to a compound of Formula (I) or a form thereof herein is understood to include reference to salt forms thereof, unless otherwise indicated.
- the term "salt(s)", as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases.
- salts of the compounds of the Formula (I) may be formed, for example, by reacting a compound of Formula (I) or a form thereof with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
- compositions include one or more salts of acidic or basic groups present in compounds described herein.
- Embodiments of acid addition salts include, and are not limited to, acetate, ascorbate, benzoate, benzenesulfonate, bisulfate, bitartrate, borate, bromide, butyrate, chloride, citrate, camphorate, camphorsulfonate, ethanesulfonate, formate, fumarate, gentisinate, gluconate, glucaronate, glutamate, iodide, isonicotinate, lactate, maleate, methanesulfonate, naphthalenesulfonate, nitrate, oxalate, pamoate, pantothenate, phosphate, propionate, saccharate, salicylate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate (also known as tosylate), triflu
- Suitable basic salts include, but are not limited to, aluminum, ammonium, calcium, lithium, magnesium, potassium, sodium and zinc salts.
- Certain compounds described herein can also form pharmaceutically acceptable salts with organic bases (for example, organic amines) such as, but not limited to, dicyclohexylamines, t-butyl amines and the like, and with various amino acids such as, but not limited to, arginine, lysine and the like.
- Basic nitrogen- containing groups may be quarternized with agents such as lower alkyl halides (e.g.
- dialkyl sulfates e.g., dimethyl, diethyl, and dibutyl sulfates
- long chain halides e.g., decyl, lauryl, and stearyl chlorides, bromides and iodides
- aralkyl halides e.g., benzyl and phenethyl bromides
- Compounds of Formula (I) and forms thereof may further exist in a tautomeric form (for example, the 4-hydroxy-2-pyridinone core of Formula (I) may exist in either the 2,4- dihydroxy-pyridine or the 2-hydroxy-4-pyridinone form). All such tautomeric forms are contemplated and intended to be included within the scope of the compounds of Formula (I) or a form thereof as described herein.
- a tautomeric form for example, the 4-hydroxy-2-pyridinone core of Formula (I) may exist in either the 2,4- dihydroxy-pyridine or the 2-hydroxy-4-pyridinone form. All such tautomeric forms are contemplated and intended to be included within the scope of the compounds of Formula (I) or a form thereof as described herein.
- the compounds of Formula (I) or a form thereof may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms.
- the present description is intended toinclude all stereoisomeric forms of the compounds of Formula (I) as well as mixtures thereof, including racemic mixtures.
- the compounds described herein may include one or more chiral centers, and as such may exist as racemic mixtures (R/S) or as substantially pure enantiomers and diastereomers.
- the compounds may also exist as substantially pure (R) or (S) enantiomers (when one chiral center is present).
- the compounds described herein are (S) isomers and may exist as enantiomerically pure compositions substantially comprising only the (S) isomer.
- the compounds described herein are (R) isomers and may exist as enantiomerically pure compositions substantially comprising only the (R) isomer.
- the compounds described herein may also exist as a (R,R), (R,S), (S,R) or (S,S) isomer, as defined by IUPAC Nomenclature Recommendations.
- substantially pure refers to compounds consisting substantially of a single isomer in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100% of the single isomer.
- a compound of Formula (I) or a form thereof is a substantially pure (S) enantiomer form present in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100%.
- a compound of Formula (I) or a form thereof is a substantially pure (R) enantiomer form present in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100%.
- racemate is any mixture of isometric forms that are not
- “enantiomeric ally pure” including mixtures such as, without limitation, in a ratio of about 50/50, about 60/40, about 70/30, or about 80/20.
- Enantiomers can be separated by use of chiral HPLC column or other chromatographic methods known to those skilled in the art. Enantiomers can also be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher' s acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Also, some of the compounds of Formula (I) may be atropisomers (e.g. , substituted biaryls) and are considered as part of this description.
- an appropriate optically active compound e.g., chiral auxiliary such as a chiral alcohol or Mosher' s acid chloride
- All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this description, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl).
- Individual stereoisomers of the compounds described herein may, for example, be substantially free of other isomers, or may be present in a racemic mixture, as described supra.
- isotopologue refers to isotopically-enriched compounds described herein which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
- isotopes that can be incorporated into compounds described herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 0, 17 0, 31 P, 32 P, 35 S, 18 F, 35 C1 and 36 C1, respectively, each of which are also within the scope of this description.
- Certain isotopically-enriched compounds described herein are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3 H) and carbon- 14 (i.e., 14 C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances.
- the present description relates to a method of use for a compound of Formula (I) or a form thereof for treating or ameliorating wild-type or drug-resistant forms of N. gonorrhoeae in a subject in need thereof, comprising administering an effective amount of the compound or a form thereof to the subject.
- the present description further relates to use of the compound of Formula (I) or a form thereof for treating or ameliorating wild-type or drug-resistant forms of N. gonorrhoeae in a subject in need thereof.
- the present description further relates to use of the compound of Formula (I) or a form thereof having activity toward wild-type or drug-resistant N. gonorrhoeae.
- the present description also relates to use of a compound of Formula (I) or a form thereof having activity against aminoglycoside-resistant, beta-lactam-resistant,
- cephalosporin-resistant macrolide-resistant, quinolone-resistant or tetracycline-resistant N. gonorrhoeae .
- the present description also relates to use of a compound of Formula (I) or a form thereof having activity against aminoglycoside-resistant (including drug-resistant forms of N. gonorrhoeae that are spectinomycin-resistant, streptomycin -resistant, and the like), beta- lactam-resistant (including drug-resistant forms of N. gonorrhoeae that are ampicillin- resistant, penicillin-resistant, and the like), cephalosporin-resistant (including drug-resistant forms of N. gonorrhoeae that are ceftriaxone-resistant, cefixime-resistant, and the like), macrolide-resistant (including drug-resistant forms of N.
- aminoglycoside-resistant including drug-resistant forms of N. gonorrhoeae that are spectinomycin-resistant, streptomycin -resistant, and the like
- beta- lactam-resistant including drug-resistant forms of N. gonorrhoeae that are ampicillin- resistant, pen
- gonorrhoeae that are azithromycin- resistant, and the like
- quinolone-resistant including drug-resistant forms of N. gonorrhoeae that are ciprofloxacin-resistant, and the like
- tetracycline-resistant N. gonorrhoeae including drug-resistant forms of N. gonorrhoeae that are tetracycline-resistant.
- the present description also relates to use of the compound of Formula (I) or a form thereof having activity against ampicillin-resistant, azithromycin-resistant, ceftriaxone- resistant, cefixime-resistant, ciprofloxacin-resistant, penicillin-resistant, spectinomycin- resistant, streptomycin-resistant and tetracycline-resistant forms of N. gonorrhoeae.
- the present description also relates to use of the compound of Formula (I) or a form thereof having activity against aminoglycoside-resistant forms of N. gonorrhoeae.
- the present description also relates to use of the compound of Formula (I) or a form thereof having activity against beta-lactam-resistant forms of N. gonorrhoeae.
- the present description also relates to use of the compound of Formula (I) or a form thereof having activity against cephalosporin-resistant forms of N. gonorrhoeae.
- the present description also relates to use of the compound of Formula (I) or a form thereof having activity against macrolide-resistant forms of N. gonorrhoeae.
- the present description also relates to use of the compound of Formula (I) or a form thereof having activity against quinolone-resistant forms of N. gonorrhoeae.
- the present description also relates to use of the compound of Formula (I) or a form thereof having activity against tetracycline-resistant forms of
- the present description also relates to use of the compound of Formula (I) or a form thereof having activity against ampicillin-resistant forms of N. gonorrhoeae.
- the present description also relates to use of the compound of Formula (I) or a form thereof having activity against azithromycin-resistant forms of N. gonorrhoeae.
- the present description also relates to use of the compound of Formula (I) or a form thereof having activity against ceftriaxone-resistant forms of N. gonorrhoeae.
- the present description also relates to use of the compound of Formula (I) or a form thereof having activity against cefixime-resistant forms of N. gonorrhoeae.
- the present description also relates to use of the compound of Formula (I) or a form thereof having activity against ciprofloxacin-resistant forms of N. gonorrhoeae.
- the present description also relates to use of the compound of Formula (I) or a form thereof having activity against penicillin-resistant forms of N. gonorrhoeae.
- the present description also relates to use of the compound of Formula (I) or a form thereof having activity against spectinomycin-resistant forms of N. gonorrhoeae.
- the present description also relates to use of the compound of Formula (I) or a form thereof having activity against streptomycin-resistant forms of N. gonorrhoeae.
- the present description also relates to use of the compound of Formula (I) or a form thereof having activity against tetracycline -resistant forms of N. gonorrhoeae.
- the present description further relates to use of the compound of Formula (I) or a form thereof in a combination therapy with known antibacterial or antibiotic agents to provide additive or synergistic activity, thus enabling the development of a combination product for the treatment of a wild-type or drug-resistant form of N. gonorrhoeae.
- the compounds of the present description have demonstrated an ability to inhibit the replication of a wide variety of N. gonorrhoeae isolates.
- the instant compounds possess in vitro activity against a wide spectrum of N. gonorrhoeae isolates which have developed resistance to almost all known treatments and are expected to successfully treat wild-type or drug-resistant forms of N. gonorrhoeae compared to current antibacterial agents.
- the compounds are also effective in vivo and lack cellular toxicity.
- the instant compounds are useful in a combination therapy with current standard of care antibacterial or antibiotic agents, having additive or synergistic activity with one or more known antibacterial or antibiotic agents.
- a combination therapy comprising compounds described herein in combination with one or more known antibacterial or antibiotic drugs may be used to treat wild-type or drug- resistant forms of N. gonorrhoeae regardless of whether N. gonorrhoeae is resistant or responsive to the known antibacterial or antibiotic drug.
- Embodiments of the present description include the use of a compound of Formula (I) or a form thereof in a combination therapy for treating or ameliorating N. gonorrhoeae in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof and an effective amount of one or more antibiotic or
- Embodiments of the present description include the use of a compound of Formula (I) or a form thereof in a combination therapy for treating or ameliorating wild-type or drug- resistant forms of N. gonorrhoeae in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof and an effective amount of one or more antibiotic or antibacterial agent(s).
- An embodiment of the present description includes the use of a compound of Formula (I) or a form thereof in the preparation of a kit comprising the compound of Formula (I) or a form thereof and instructions for administering an effective amount of the compound of Formula (I) or a form thereof and an effective amount of one or more antibiotic or
- the agents used in the combination therapy may include, without limitation, one or more agents selected from Amikacin, Amoxicillin, Ampicillin,
- Carbenicillin Cefaclor, Cefadroxil, Cefalexin, Cefalotin, Cefamandole, Cefazolin, Cefdinir, Cefditoren, Cefixime, Cefoperazone, Cefotaxime, Cefoxitin, Cefpodoxime, Cefprozil, Ceftazidime, Ceftibuten, Ceftizoxime, Ceftriaxone, Cefuroxime, Chloramphenicol, Cilastatin, Ciprofloxacin, Clarithromycin, Clavulanate, Clindamycin, Clofazimine, CloxaciUin, Colistin, Cycloserine, Dalfopristin, Dapsone, Daptomycin, Dicloxacillin, Dirithromycin, Doripenem, Doxycycline, Enoxacin, Erythromycin, Ethambutol, Ethionamide, Flucloxacillin,
- Mafenide Meropenem, Methicillin, Metronidazole, Mezlocillin, Minocycline, Moxifloxacin, Mupirocin, Nafcillin, Nalidixic acid, Neomycin, Netilmicin, Nitrofurantoin, Norfloxacin, Ofloxacin, Oxacillin, Oxytetracycline, Paromomycin, Penicillin G, Penicillin V, Piperacillin, Platensimycin, Polymyxin B, Pyrazinamide, Quinupristin, Rapamycin, Rifabutin, Rifampicin, Rifampin, Rifapentine, Rifaximin, Roxithromycin, Silver sulfadiazine, Solithromycin, Spectinomycin, Streptomycin, Sulbactam, Sulfacetamide, Sulfadiazine, Sulfamethizole, Sulfamethoxazole, Sulfanamide, Sulfasalazine, Sulf
- Tigecycline Tinidazole, Tobramycin, Trimethoprim, Troleandomycin or Vancomycin.
- the agents used in the combination therapy may include, without limitation, one or more agents selected from Amikacin, Amoxicillin, Arsphenamine, Azlocillin, Aztreonam, Bacitracin, Capreomycin, Carbenicillin, Cefaclor, Cefadroxil, Cefalexin, Cefalotin (Cefalothin), Cefamandole, Cefazolin, Cefdinir, Cefditoren,
- Cefoperazone Cefotaxime, Cefoxitin, Cefpodoxime, Cefprozil, Ceftazidime, Ceftibuten, Ceftizoxime, Cefuroxime, Chloramphenicol, Cilastatin, Clarithromycin, Clavulanate, Clindamycin, Clofazimine, Cloxacillin, Colistin, Cycloserine, Dalfopristin, Dapsone, Daptomycin, Dicloxacillin, Dirithromycin, Doripenem, Doxycycline, Enoxacin,
- Roxithromycin Silver sulfadiazine, Solithromycin, Sulbactam, Sulfacetamide, Sulfadiazine, Sulfamethizole, Sulfamethoxazole, Sulfanilimide, Sulfasalazine, Sulfisoxazole, Tazobactam, Teicoplanin, Telavancin, Telithromycin, Temocillin, Thiamphenicol, TicarciUin, Tigecycline, Tinidazole, Tobramycin, Trimethoprim, Troleandomycin or Vancomycin.
- the agents used in the combination therapy may include, without limitation, one or more agents selected from Amoxicillin, Ampicillin, Azithromycin, Ciprofloxacin, Doxycycline, Enoxacin, Erythromycin, Gatifloxacin, Gemifloxacin,
- Gentamicin Levofloxacin, Lomefloxacin, Moxifloxacin, Nalidixic acid, Norfloxacin, Ofloxacin, Rapamycin, Solithromycin, Spectinomycin, Streptomycin, Tetracycline or Vancomycin.
- the agents used in the combination therapy may particularly include one or more agents selected from Amoxicillin, Azithromycin, Ciprofloxacin, Doxycycline, Enoxacin, Erythromycin, Gatifloxacin, Gemifloxacin, Gentamicin,
- the agents used in the combination therapy may include, without limitation, one or more agents selected from Ampicillin, Azithromycin, Cefixime, Ceftriaxone, Ciprofloxacin, Penicillin G, Penicillin V, Spectinomycin, Streptomycin or Tetracycline.
- the present description relates to use of a compound of Formula (I) or a form thereof for treating or ameliorating wild- type forms of N. gonorrhoeae, for treating or ameliorating drug-resistant forms of N. gonorrhoeae or for treating or ameliorating multidrug resistant forms of N. gonorrhoeae.
- One embodiment of the use of the present description relates to use of a compound of Formula (I) or a form thereof for treating or ameliorating N. gonorrhoeae in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof to the subject.
- One embodiment of the use of the present description relates to use of a compound of Formula (I) or a form thereof for treating or ameliorating N. gonorrhoeae resulting from wild-type forms of N. gonorrhoeae in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof to the subject.
- One embodiment of the use of the present description relates to use of a compound of Formula (I) or a form thereof for treating or ameliorating N. gonorrhoeae resulting from drug-resistant forms of N. gonorrhoeae in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof to the subject.
- One embodiment of the use of the present description relates to a method of use for a compound of Formula (I) or a form thereof for treating or ameliorating N. gonorrhoeae in a subject in need thereof, comprising administering an effective amount of the compound to the subject.
- One embodiment of the use of the present description relates to a method of use for a compound of Formula (I) or a form thereof for treating or ameliorating wild-type or drug-resistant forms N. gonorrhoeae in a subject in need thereof, comprising administering an effective amount of the compound to the subject.
- One embodiment of the use of the present description relates to a method of use for a compound of Formula (I) or a form thereof for treating or ameliorating wild-type or drug-resistant forms N. gonorrhoeae in a subject in need thereof, comprising administering an effective amount of the compound to the subject.
- One embodiment of the use of the present description relates to a method of use for a compound of Formula (I) or a form thereof for treating or ameliorating wild-type forms of N. gonorrhoeae in a subject in need thereof, comprising administering an effective amount of the compound to the subject.
- One embodiment of the use of the present description relates to a method of use for a compound of Formula (I) or a form thereof for treating or ameliorating wild-type forms of N. gonorrhoeae in a subject in need thereof, comprising administering an effective amount of the compound to the subject.
- One embodiment of the use of the present description relates to a method of use for a compound of Formula (I) or a form thereof for treating or ameliorating drug-resistant forms of N. gonorrhoeae in a subject in need thereof, comprising administering an effective amount of the compound to the subject.
- One embodiment of the use of the present description relates to use of a compound of Formula (I) or a form thereof in the manufacture of a medicament for treating or ameliorating N. gonorrhoeae in a subject in need thereof, comprising administering an effective amount of the medicament to the subject.
- One embodiment of the use of the present description relates to use of a compound of Formula (I) or a form thereof in the manufacture of a medicament for treating or ameliorating wild-type or drug-resistant forms of N. gonorrhoeae in a subject in need thereof, comprising administering an effective amount of the medicament to the subject.
- One embodiment of the use of the present description relates to use of a compound of Formula (I) or a form thereof in the manufacture of a medicament for treating or ameliorating wild-type forms of N. gonorrhoeae in a subject in need thereof, comprising administering an effective amount of the medicament to the subject.
- One embodiment of the use of the present description relates to use of a compound of Formula (I) or a form thereof in the preparation of a kit comprising the compound of Formula (I) or a form thereof and instructions for administering the compound for treating or ameliorating N. gonorrhoeae in a subject in need thereof.
- One embodiment of the use of the present description relates to a method of use for a compound of Formula (I) or a form thereof for treating or ameliorating N. gonorrhoeae in a subject in need thereof, comprising administering an effective amount of a compound of Formula (I) or a form thereof to the subject.
- the subject is treatment naive. In another respect, for each of such embodiments, the subject is not treatment naive.
- treating refers to: (i) preventing a disease, disorder or condition from occurring in a subject that may be predisposed to the disease, disorder and/or condition but has not yet been diagnosed as having the disease, disorder and/or condition; (ii) inhibiting a disease, disorder or condition, i.e., arresting the development thereof; and/or (iii) relieving a disease, disorder or condition, i.e., causing regression of the disease, disorder and/or condition.
- the term "subject” refers to an animal or any living organism having sensation and the power of voluntary movement, and which requires oxygen and organic food.
- Nonlimiting examples include members of the human, primate, equine, porcine, bovine, murine, rattus, canine and feline specie.
- the subject is a mammal or a warm-blooded vertebrate animal. In other embodiments, the subject is a human.
- the term “patient” may be used interchangeably with “subject” and "human”.
- Another aspect of the description particularly relates to a method of use for a compound of Formula (I) or a form thereof for treating or ameliorating N. gonorrhoeae resulting from wild type forms of N. gonorrhoeae in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or a form thereof.
- Another aspect of the description particularly relates to a method of use for a compound of Formula (I) or a form thereof for treating or ameliorating N. gonorrhoeae resulting from drug-resistant forms of N. gonorrhoeae in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or a form thereof.
- One aspect of the description relates to a method of use for a compound of Formula (I) or a form thereof for treating or ameliorating N. gonorrhoeae in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or a form thereof having activity against N.
- Another aspect of the description relates to a method of use for a compound of Formula (I) or a form thereof for treating or ameliorating N. gonorrhoeae in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or a form thereof having activity against N. gonorrhoeae isolates engineered from clinical isolate FA 19 to contain mutations in gyrA and parC, including those selected from ciprofloxacin-resistant (ciprofloxacin ) N. gonorrhoeae AK1 (gyrAgi / g 5 ) and
- Another aspect of the description relates to a method of use for a compound of
- Formula (I) or a form thereof for treating or ameliorating N. gonorrhoeae in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I) or a form thereof having activity against N. gonorrhoeae World Health
- WHO World Health Organization
- isolates selected from: tetracycline ER N. gonorrhoeae 13477 (WHO tetracycline intermediate resistant isolate F), ciprofloxacin ER /tetracycline R N. gonorrhoeae 13478 (WHO ciprofloxacin intermediate resistant and tetracycline resistant isolate G), quinoline N. gonorrhoeae 13479 (WHO quinolone high level resistant isolate K), MDR N. gonorrhoeae 13480 (WHO multi-drug resistant isolate L) and MD ⁇ R N.
- WHO tetracycline ER N. gonorrhoeae 13477
- ciprofloxacin ER /tetracycline R N. gonorrhoeae 13478 WHO ciprofloxacin intermediate resistant and tetracycline resistant isolate G
- gonorrhoeae 13481 WHO multi-drug intermediate resistant isolate M
- Unemo M Fasth O, Fredlund H, Limnios A, Tapsall J. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J.
- Another aspect of the description relates to a method of use for a compound of Formula (I) or a form thereof for treating or ameliorating N. gonorrhoeae in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or a form thereof having activity against the
- Another aspect of the description relates to a method of use for a compound of
- Formula (I) or a form thereof for treating or ameliorating N. gonorrhoeae in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I) or a form thereof having activity against a N. gonorrhoeae isolate engineered from WHO isolate F (N. gonorrhoeae 13477), where DNA from FA1090 was isolated and used to transform 13477 with the streptomycin determinant.
- the resulting isolate SP1364 is streptomycin at >1250 ⁇ g/mL.
- Another aspect of the description relates to a method of use for a compound of Formula (I) or a form thereof for treating or ameliorating N. gonorrhoeae in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or a form thereof having activity against a N. gonorrhoeae clinical isolate LG24 (see, Garvin LE, Bash MC, Keys C, Warner DM, Ram S, Shafer WM and Jerse AE.
- Another aspect of the description relates to a method of use for a compound of
- Formula (I) or a form thereof for treating or ameliorating N. gonorrhoeae in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I) or a form thereof having activity against N. gonorrhoeae clinical isolates selected from penicillin-resistant (penicillin ) N. gonorrhoeae LGB3, tetracycline-resistant
- An embodiment of the use of a compound of Formula (I) or a form thereof includes a method of use for a compound of Formula (I) or a form thereof to treat or ameliorate wild- type N. gonorrhoeae 49226 in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof to the subject.
- An embodiment of the use of a compound of Formula (I) or a form thereof includes a method of use for a compound of Formula (I) or a form thereof to treat or ameliorate clinical isolate N. gonorrhoeae LG24 in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof to the subject.
- An embodiment of the use of a compound of Formula (I) or a form thereof includes a method of use for a compound of Formula (I) or a form thereof to treat or ameliorate
- An embodiment of the use of a compound of Formula (I) or a form thereof includes a method of use for a compound of Formula (I) or a form thereof to treat or ameliorate ampicillin N. gonorrhoeae LGB50 in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof to the subject.
- An embodiment of the use of a compound of Formula (I) or a form thereof includes a method of use for a compound of Formula (I) or a form thereof to treat or ameliorate penicillin-sensitive N. gonorrhoeae FA19 or LGB3 in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof to the subject.
- An embodiment of the use of a compound of Formula (I) or a form thereof includes a method of use for a compound of Formula (I) or a form thereof to treat or ameliorate streptomycin N. gonorrhoeae FA 1090 or SP1364 in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof to the subject.
- An embodiment of the use of a compound of Formula (I) or a form thereof includes a method of use for a compound of Formula (I) or a form thereof to treat or ameliorate ciprofloxacin N. gonorrhoeae AK1 or AK2 in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof to the subject.
- An embodiment of the use of a compound of Formula (I) or a form thereof includes a method of use for a compound of Formula (I) or a form thereof to treat or ameliorate N. gonorrhoeae caused by an isolate selected from 13477, 13478, 13479, 13480 or 13481 in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof to the subject.
- An embodiment of the use of a compound of Formula (I) or a form thereof includes a method of use for a compound of Formula (I) or a form thereof to treat or ameliorate tetracycline N. gonorrhoeae LGB24 in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof to the subject.
- An embodiment of the use of a compound of Formula (I) or a form thereof includes a method of use for a compound of Formula (I) or a form thereof to treat or ameliorate ciprofloxacin XDR /cefixime XDR /ceftriaxone XDR N. gonorrhoeae F89 in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof to the subject.
- the terms "effective amount” or “therapeutically effective amount” mean an amount of compound of Formula (I) or a form, composition or medicament thereof effective in inhibiting the above-noted diseases and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect in a subject in need thereof.
- the dose administered to achieve an effective target plasma concentration may also be administered based upon the weight of the subject or patient.
- Doses administered on a weight basis may be in the range of about 0.001 mg/kg/day to about 3500 mg/kg/day, or about 0.01 mg/kg/day to about 2000 mg/kg/day, or about 0.01 mg/kg/day to about 1500 mg/kg/day, or about 0.01 mg/kg/day to about 1000 mg/kg/day, or about 0.01 mg/kg/day to about 600 mg/kg/day, or about 0.01 mg/kg/day to about 500 mg/kg/day, or about 0.01 mg/kg/day to about 300 mg/kg/day, or about 0.015 mg/kg/day to about 200 mg/kg/day, or about 0.02 mg/kg/day to about 100 mg/kg/day, or about 0.025 mg/kg/day to about 100 mg/kg/day, or about 0.03 mg/kg/day to about 100 mg/kg/day, wherein said amount is orally administered once (once in
- the effective amount will be in a range of from about 0.001 mg/kg/day to about 500 mg/kg/day, or about 0.01 mg/kg/day to about 500 mg/kg/day, or about 0.1 mg to about 500 mg/kg/day, or about 1.0 mg/day to about 500 mg/kg/day, in single, divided, or a continuous dose for a patient or subject having a weight in a range of between about 40 to about 200 kg (which dose may be adjusted for patients or subjects above or below this range, particularly children under 40 kg).
- the typical adult subject is expected to have a median weight in a range of about 70 kg.
- compounds described herein may be formulated for delivery at about 0.02, 0.025, 0.03, 0.05, 0.06, 0.075, 0.08, 0.09, 0.10, 0.20, 0.25, 0.30, 0.50, 0.60, 0.75, 0.80, 0.90, 1.0, 1.10, 1.20, 1.25, 1.50, 1.75, 2.0, 3.0, 5.0, 10, 20, 30, 40, 50, 100, 150, 200, 250, 300, 400 or 500 mg/kg/day.
- Daily doses adjusted based upon the weight of the subject or patient may be administered as a single, divided, or continuous dose. In embodiments where a dose of compound is given more than once per day, the dose may be administered twice, thrice, or more per day.
- the "effective amount" of a compound of Formula (I) or a form thereof for use in the manufacture of a medicament, the preparation of a pharmaceutical kit or in a method of treating or ameliorating N. gonorrhoeae in a subject in need thereof is intended to include an amount in a range of from about 0.001 mg to about 3500 mg administered daily; 1.0 mg to about 3500 mg administered daily; 1.0 mg to about 1500 mg administered daily; 1.0 mg to about 1000 mg administered daily; 10.0 mg to about 600 mg administered daily; 0.5 mg to about 2000 mg administered daily; or, an amount in a range of from about 5.0 mg to about 300 mg administered daily.
- the effective amount may be the amount required to treat
- the desired effect can be determined by analyzing the presence of bacterial DNA.
- the effective amount for a subject will depend upon various factors, including the subject's body weight, size and health. Effective amounts for a given patient can be determined by routine experimentation that is within the skill and judgment of the clinician.
- the effective amount can be estimated initially either in cell culture assays or in relevant animal models, such as a mouse, chimpanzee, marmoset or tamarin animal model. Relevant animal models may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
- Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED 50 (the dose therapeutically effective in 50% of the population) and LD 50 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is therapeutic index, and can be expressed as the ratio, LD 50 /ED 50 .
- the effective amount is such that a large therapeutic index is achieved.
- the dosage is within a range of circulating concentrations that include an ED 50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.
- concentration-biological effect relationships observed with regard to a compound of Formula (I) or a form thereof indicate a target plasma concentration ranging from approximately 0.001 ⁇ g/mL to approximately 50 ⁇ g/mL, from approximately 0.01 ⁇ g/mL to approximately 20 ⁇ g/mL, from approximately 0.05 ⁇ g/mL to approximately 10 ⁇ g/mL, or from approximately 0.1 ⁇ g/mL to approximately 5 ⁇ g/mL.
- the compounds described herein may be administered at doses that vary, such as, for example, without limitation, from 0.1 ng to 10,000 mg, depending upon the route of administration in single, divided, or continuous doses for a patient weighing between about 10 to about 100 kg (which dose may be adjusted for patients within this weight range, particularly for children under 40 kg).
- Dosage and administration may be adjusted to provide sufficient levels of the active agent(s) or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, general health of the subject, ethinicity, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, experience with other antibacterial therapies, and tolerance/response to therapy.
- Long-acting pharmaceutical compositions may be administered every 2, 3 or 4 days, once every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.
- the compounds and compositions described herein may be administered to the subject via any drug delivery route known in the art.
- Nonlimiting examples include oral, ocular, rectal, buccal, topical, nasal, ophthalmic, subcutaneous, intramuscular, intraveneous (bolus and infusion), intracerebral, transdermal, and pulmonary routes of administration.
- Metabolites of the Compounds include oral, ocular, rectal, buccal, topical, nasal, ophthalmic, subcutaneous, intramuscular, intraveneous (bolus and infusion), intracerebral, transdermal, and pulmonary routes of administration.
- the description includes the use of compounds produced by a process comprising contacting a compound described herein with a mammalian tissue or a mammal for a period of time sufficient to yield a metabolic product thereof.
- Such products typically are identified by preparing a radio-labeled isotopologue (e.g.,
- a detectable dose e.g., greater than about 0.5 mg/kg
- a mammal such as a rat, mouse, guinea pig, dog, monkey or human
- sufficient time for metabolism to occur typically about 30 seconds to about 30 hours
- the conversion products are easily isolated since they are "radiolabeled" by virtue of being isotopically-enriched (others are isolated by the use of antibodies capable of binding epitopes surviving in the metabolite).
- the metabolite structures are determined in conventional fashion, e.g., by MS or NMR analysis.
- Embodiments of the present description include the use of a compound of Formula (I) or a form thereof in a pharmaceutical composition for treating or ameliorating
- N. gonorrhoeae in a subject in need thereof comprising administering an effective amount of the compound of Formula (I) or a form thereof in admixture with one or more
- Embodiments of the present description include the use of a compound of Formula (I) or a form thereof in a pharmaceutical composition for treating or ameliorating wild-type or drug-resistant forms of N. gonorrhoeae in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof in admixture with one or more pharmaceutically acceptable excipient(s).
- composition means a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
- the pharmaceutical composition may be formulated to achieve a physiologically compatible pH, ranging from about pH 3 to about pH 11. In some embodiments, the pharmaceutical composition is formulated to achieve a pH of from about pH 3 to about pH 7. In other embodiments, the pharmaceutical composition is formulated to achieve a pH of from about pH 5 to about pH 8.
- pharmaceutically acceptable excipient refers to an excipient for administration of a pharmaceutical agent, such as the compounds described herein.
- the term refers to any pharmaceutical excipient that may be administered without undue toxicity.
- Pharmaceutically acceptable excipients may be determined in part by the particular composition being administered, as well as by the particular mode of administration and/or dosage form.
- Nonlimiting examples of pharmaceutically acceptable excipients include carriers, solvents, stabilizers, adjuvants, diluents, etc. Accordingly, there exists a wide variety of suitable formulations of pharmaceutical compositions for the instant compoounds described herein ⁇ see, e.g., Remington's Pharmaceutical Sciences).
- Suitable excipients may be carrier molecules that include large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive antibodies.
- Other exemplary excipients include antioxidants such as ascorbic acid; chelating agents such as EDTA;
- hydroxyalkylcellulose hydroxyalkylmethylcellulose ⁇ e.g., hydroxypropylmethylcellulose, also known as HPMC
- stearic acid liquids such as oils, water, saline, glycerol and ethanol; wetting or emulsifying agents; pH buffering substances; and the like.
- Liposomes are also included within the definition of pharmaceutically acceptable excipients.
- compositions described herein may be formulated in any form suitable for the intended use described herein.
- suitable formulations for oral administration include solids, liquid solutions, emulsions and suspensions, while suitable inhaleable formulations for pulmonary administration include liquids and powders.
- Alternative formulations include syrups, creams, ointments, tablets, and lyophilized solids which can be reconstituted with a physiologically compatible solvent prior to administration.
- tablets, troches, lozenges, aqueous or oil suspensions, non-aqueous solutions, dispersible powders or granules (including micronized particles or nanoparticles), emulsions, hard or soft capsules, syrups or elixirs may be prepared.
- compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents including sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide a palatable preparation.
- compositions suitable for use in conjunction with tablets include, for example, inert diluents, such as celluloses, calcium or sodium carbonate, lactose, calcium or sodium phosphate; disintegrating agents, such as croscarmellose sodium, cross- linked povidone, maize starch, or alginic acid; binding agents, such as povidone, starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated by known techniques including
- microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.
- Formulations for oral use may be also presented as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent, for example celluloses, lactose, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with non-aqueous or oil medium, such as glycerin, propylene glycol, polyethylene glycol, peanut oil, liquid paraffin or olive oil.
- an inert solid diluent for example celluloses, lactose, calcium phosphate or kaolin
- non-aqueous or oil medium such as glycerin, propylene glycol, polyethylene glycol, peanut oil, liquid paraffin or olive oil.
- compositions described herein may be formulated as suspensions comprising a compound of Formula (I) or a form thereof in admixture with one or more pharmaceutically acceptable excipient(s) suitable for the manufacture of a suspension.
- pharmaceutical compositions described herein may be formulated as dispersible powders and granules suitable for preparation of a suspension by the addition of one or more excipient(s).
- Excipients suitable for use in connection with suspensions include suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcelluose, sodium alginate, polyvinylpyrrolidone, gum tragacanth, gum acacia, dispersing or wetting agents such as a naturally occurring phosphatide (e.g. , lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g. , polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g.
- suspending agents such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcelluose, sodium alginate, polyvinylpyrrolidone, gum tragacanth, gum acacia
- dispersing or wetting agents such as a naturally occurring phosphatide (e.g. , lecithin), a condensation product of an alkylene oxide with a fatty
- heptadecaethyleneoxycethanol a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g. , polyoxyethylene sorbitan monooleate); and thickening agents, such as carbomer, beeswax, hard paraffin or cetyl alcohol.
- the suspensions may also contain one or more preservatives such as acetic acid, methyl and/or n-propyl p-hydroxy-benzoate; one or more coloring agents; one or more flavoring agents; and one or more sweetening agents such as sucrose or saccharin.
- the pharmaceutical compositions described herein may also be in the form of oil-in- water emulsions.
- the oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these.
- Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth; naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids;
- hexitol anhydrides such as sorbitan monooleate
- condensation products of these partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate
- the emulsion may also contain sweetening and flavoring agents.
- Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose.
- Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
- compositions described herein may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous emulsion or oleaginous suspension.
- a sterile injectable preparation such as a sterile injectable aqueous emulsion or oleaginous suspension.
- emulsion or suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,2-propane-diol.
- the sterile injectable preparation may also be prepared as a lyophilized powder.
- acceptable vehicles and solvents that may be employed are water, Ringer' s solution, and isotonic sodium chloride solution.
- sterile fixed oils may be employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or di-glycerides.
- fatty acids such as oleic acid may likewise be used in the preparation of injectables.
- the compounds described herein may be substantially insoluble in water and sparingly soluble in most pharmaceutically acceptable protic solvents and vegetable oils, but generally soluble in medium-chain fatty acids (e.g. , caprylic and capric acids) or triglycerides and in propylene glycol esters of medium-chain fatty acids.
- medium-chain fatty acids e.g. , caprylic and capric acids
- propylene glycol esters of medium-chain fatty acids e.g., caprylic and capric acids
- contemplated in the description are compounds which have been modified by substitutions or additions of chemical or biochemical moieties which make them more suitable for delivery (e.g., increase solubility, bioactivity, palatability, decrease adverse reactions, etc.), for example by esterification, glycosylation, PEGylation, etc.
- the compound described herein is formulated for oral administration in a lipid-based composition suitable for low solubility compounds.
- Lipid- based formulations can generally enhance the oral bioavailability of such compounds.
- pharmaceutical compositions described herein may comprise a effective amount of a compound of Formula (I) or a form thereof, together with at least one pharmaceutically acceptable excipient selected from medium chain fatty acids or propylene glycol esters thereof (e.g., propylene glycol esters of edible fatty acids such as caprylic and capric fatty acids) and pharmaceutically acceptable surfactants, such as polysorbate 20 or 80 (also referred to as Tween 20 or Tween 80, respectively) or polyoxyl 40 hydrogenated castor oil.
- pharmaceutically acceptable excipient selected from medium chain fatty acids or propylene glycol esters thereof (e.g., propylene glycol esters of edible fatty acids such as caprylic and capric fatty acids) and pharmaceutically acceptable surfactants, such as polysorbate 20 or 80 (also referred
- bioavailability of low solubility compounds may be enhanced using particle size optimization techniques including the preparation of
- nanoparticles or nanosuspensions using techniques known to those skilled in the art.
- the compound forms present in such preparations include amorphous, partially amorphous, partially crystalline or crystalline forms.
- the pharmaceutical composition may further comprise one or more aqueous solubility enhancer(s), such as a cyclodextrin.
- a cyclodextrin include hydroxypropyl, hydroxyethyl, glucosyl, maltosyl and maltotriosyl derivatives of ⁇ -, ⁇ -, and ⁇ -cyclodextrin, and hydroxypropyl- ⁇ -cyclodextrin (HPBC).
- HPBC hydroxypropyl- ⁇ -cyclodextrin
- the pharmaceutical composition further comprises HPBC in a range of from about 0.1% to about 20%, from about 1% to about 15%, or from about 2.5% to about 10%.
- the amount of solubility enhancer employed may depend on the amount of the compound in the composition.
- Rx2 Rsb or CH 2 OTBS
- Halogenated pyridones of Type lc (where Hal represents a halogen such as CI) are prepared through the reaction of nitriles of Type lb with malonyl halides of Type la.
- Pyridines of Type Id are prepared from pyridones of Type lc via Mitsunobu reaction with a suitable dialkyl azodicarboxylate (such as diisopropyl azodicarboxylate and the like) and benzyl alcohol.
- a suitable dialkyl azodicarboxylate such as diisopropyl azodicarboxylate and the like
- Functionalized pyridines of Type le are prepared from pyridines of Type Id via deprotonation of pyridine of Type Id with an appropriate alkyl lithium species (such as n- BuLi and the like) followed by reaction with benzylchloroformate.
- an appropriate alkyl lithium species such as n- BuLi and the like
- Boronic ester intermediates of Type lg are prepared from aryl halides of Type If (where Hal represents a halogen such as Br or I, R xl is either Rs a or a suitable protecting group such as Boc, and R x2 is R 5b or CH 2 OTBS (CH 2 -0-tert-butyldimethylsilyl)) via a Miyaura borylation reaction with a suitable Pd catalyst (such as PdCl 2 (dppf) and the like) and an appropriate diboron ester (such as 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-l,3,2- dioxaborolane and the like).
- a suitable Pd catalyst such as PdCl 2 (dppf) and the like
- diboron ester such as 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-l,3,2- dioxaborolane and the
- Biaryl intermediates of Type lh are prepared from the respective boronic esters of Type lg via Pd catalyzed Suzuki coupling with functionalized pyridines of Type le in the presence of a suitable phosphine ligand (such as t-Bu 3 P and the like) in a suitable biphasic mixture (such as a mixture of THF and water and the like).
- a suitable phosphine ligand such as t-Bu 3 P and the like
- a suitable biphasic mixture such as a mixture of THF and water and the like.
- Compounds of Type li are prepared from biaryl intermediates of Type lh by global benzyl group deprotection via suitable methods (such as hydrogenation in the presence of a suitable Pd catalyst (such as Pd/C and the like) or treatment with a suitable acid (such as TFA and the like).
- suitable methods such as hydrogenation in the presence of a suitable Pd catalyst (such as Pd/C and the like) or treatment with a suitable acid (such as TFA and the like).
- Boronic ester intermediates of Type 2b are prepared from 6-haloindoles of Type 2a (where Hal represents a halogen such as Br or I) via a Miyaura borylation reaction with a suitable Pd catalyst (such as PdCl 2 (dppf) and the like) and an appropriate diboron ester (such as 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-l,3,2-dioxaborolane and the like).
- a suitable Pd catalyst such as PdCl 2 (dppf) and the like
- diboron ester such as 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-l,3,2-dioxaborolane and the like.
- Biaryl pyridines of Type 2c are prepared from the corresponding boronic esters of
- Type 2b through a Pd catalyzed Suzuki coupling with functionalized pyridines of Type le in the presence of a suitable phosphine ligand (such as t-Bu 3 P and the like) in a suitable biphasic mixture (such as a mixture of THF and water and the like).
- a suitable phosphine ligand such as t-Bu 3 P and the like
- a suitable biphasic mixture such as a mixture of THF and water and the like.
- Indoles of Type 2d are prepared from the corresponding N-Boc amines of Type 2c via Boc cleavage using a suitable acid (such as TFA and the like) followed by treatment with an appropriate aldehyde in the presence of a hydride source (such as NaBH(OAc) 3 and the like).
- a suitable acid such as TFA and the like
- an appropriate aldehyde in the presence of a hydride source (such as NaBH(OAc) 3 and the like).
- Compounds of Type 2e are prepared via global benzyl group deprotection of pyridines of Type 2d with a suitable acid (such as TFA and the like).
- Amides of Type 3b are prepared via treatment of oximes of Type 3a (where Hal represents a halogen such as Br or I) with an acid (such as PPA and the like).
- Boc-protected amines of Type 3c are prepared via reduction of amides of Type 3b with a suitable hydride source (such as borane and the like) followed by treatment with Boc 2 0.
- a suitable hydride source such as borane and the like
- Boronic ester intermediates of Type 3d are prepared from amines of Type 3c via a Miyaura borylation reaction with a suitable Pd catalyst (such as PdCl 2 (dppf) and the like) and an appropriate diboron ester (such as 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-l,3,2- dioxaborolane and the like).
- a suitable Pd catalyst such as PdCl 2 (dppf) and the like
- diboron ester such as 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-l,3,2- dioxaborolane and the like.
- Biaryl pyridines of Type 3e are prepared from the corresponding boronic esters of Type 3d through a Pd catalyzed Suzuki coupling with functionalized pyridines of Type le in the presence of a suitable phosphine ligand (such as t-Bu 3 P and the like) in a suitable biphasic mixture (such as a mixture of THF and water and the like).
- a suitable phosphine ligand such as t-Bu 3 P and the like
- a suitable biphasic mixture such as a mixture of THF and water and the like.
- Substituted biaryl pyridines of Type 3f are prepared from the corresponding N-Boc amines of Type 3e via Boc cleavage using a suitable acid (such as TFA and the like) followed by treatment with an appropriate aldehyde in the presence of a hydride source (such as NaBH(OAc) 3 and the like).
- a suitable acid such as TFA and the like
- an appropriate aldehyde in the presence of a hydride source (such as NaBH(OAc) 3 and the like).
- Compounds of Type 3g are prepared via global benzyl group deprotection of pyridines of Type 3f with a suitable acid (such as TFA and the like).
- Boronic ester intermediates of Type 4b are prepared from 6-haloindoles of Type 4a (where Hal represents a halogen such as Br or I) via a Miyaura borylation reaction with a suitable Pd catalyst (such as PdCl 2 (dppf) and the like) and an appropriate diboron ester (such as 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-l,3,2-dioxaborolane and the like).
- a suitable Pd catalyst such as PdCl 2 (dppf) and the like
- diboron ester such as 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-l,3,2-dioxaborolane and the like.
- Biaryl pyridines of Type 4c are prepared from the corresponding boronic esters of
- Type 4b through a Pd catalyzed Suzuki coupling with functionalized pyridines of Type le in the presence of a suitable phosphine ligand (such as t-Bu 3 P and the like) in a suitable biphasic mixture (such as a mixture of THF and water and the like).
- a suitable phosphine ligand such as t-Bu 3 P and the like
- a suitable biphasic mixture such as a mixture of THF and water and the like.
- Step 1 reductive amination with a primary alkylamine in the presence of a hydride source (such as NaBH 4 and the like);
- Step 2 reductive amination with an appropriate aldehyde in the presence of a hydride source (such as NaBH(OAc) 3 and the like);
- Step 3 global benzyl group deprotection with a suitable acid (such as TFA and the like).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne l'utilisation de composés 2-pyridinone substitués par des anneaux bicycliques et tricycliques et des formes de ceux-ci pour traiter ou améliorer Neisseria gonorrhoeae.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462048166P | 2014-09-09 | 2014-09-09 | |
US62/048,166 | 2014-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016039939A1 true WO2016039939A1 (fr) | 2016-03-17 |
Family
ID=55459412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/045440 WO2016039939A1 (fr) | 2014-09-09 | 2015-08-15 | Composés 2-pyridinone antibactériens à substitution bicyclique et tricyclique |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016039939A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018037223A1 (fr) * | 2016-08-22 | 2018-03-01 | Discuva Ltd. | Composés antibiotiques |
US11130740B2 (en) | 2017-04-25 | 2021-09-28 | Arbutus Biopharma Corporation | Substituted 2,3-dihydro-1H-indene analogs and methods using same |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4278681A (en) * | 1979-03-12 | 1981-07-14 | Warner-Lambert Co. | Antibacterial amide compounds and means for using the same |
WO2013033258A1 (fr) * | 2011-08-29 | 2013-03-07 | Ptc Therapeutics, Inc. | Composés antibactériens et leurs méthodes d'utilisation |
WO2013033240A1 (fr) * | 2011-08-29 | 2013-03-07 | Ptc Therapeutics, Inc. | Composés antibactériens et procédés destinés à leur utilisation |
WO2014022613A1 (fr) * | 2012-08-01 | 2014-02-06 | Musc Foundation For Research Development | Compositions antibactériennes et procédés antibactériens |
-
2015
- 2015-08-15 WO PCT/US2015/045440 patent/WO2016039939A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4278681A (en) * | 1979-03-12 | 1981-07-14 | Warner-Lambert Co. | Antibacterial amide compounds and means for using the same |
WO2013033258A1 (fr) * | 2011-08-29 | 2013-03-07 | Ptc Therapeutics, Inc. | Composés antibactériens et leurs méthodes d'utilisation |
WO2013033240A1 (fr) * | 2011-08-29 | 2013-03-07 | Ptc Therapeutics, Inc. | Composés antibactériens et procédés destinés à leur utilisation |
WO2014022613A1 (fr) * | 2012-08-01 | 2014-02-06 | Musc Foundation For Research Development | Compositions antibactériennes et procédés antibactériens |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018037223A1 (fr) * | 2016-08-22 | 2018-03-01 | Discuva Ltd. | Composés antibiotiques |
US11130740B2 (en) | 2017-04-25 | 2021-09-28 | Arbutus Biopharma Corporation | Substituted 2,3-dihydro-1H-indene analogs and methods using same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11638706B2 (en) | Methods for treating Huntington's disease | |
AU2012301953C1 (en) | Antibacterial compounds and methods for use | |
US9650395B2 (en) | Antibacterial compounds and methods for use | |
EP2750678B1 (fr) | Composés antibactériens et procédés pour leur utilisation | |
WO2016025933A2 (fr) | Composes antibacteriens polycycliques substitues | |
TW201319063A (zh) | 以四氫噻唑衍生物或其鹽為有效成分之醫藥品 | |
JP5769733B2 (ja) | ピラゾロピリジンキナーゼ阻害剤 | |
WO2016039938A1 (fr) | Composés 2-pyridinone polycycliques antibactériens | |
WO2016039939A1 (fr) | Composés 2-pyridinone antibactériens à substitution bicyclique et tricyclique | |
WO2016109706A1 (fr) | Composés antibactériens de 2-pyridinone polycyclique | |
WO2016025932A1 (fr) | Composés antibactériens polycycliques substitués | |
WO2016039937A1 (fr) | Composés 2-pyridinone substitués bicycliques et tricycliques antibactériens | |
CN111377906B (zh) | 取代的吡嗪化合物及其制备方法和用途 | |
WO2016039936A2 (fr) | Composés 2-pyridinone substitués monocycliques antibactériens | |
NZ623063B2 (en) | Antibacterial compounds and methods for use | |
NZ623056B2 (en) | Antibacterial compounds and methods for use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15840877 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15840877 Country of ref document: EP Kind code of ref document: A1 |